Page last updated: 2024-11-04

ebselen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ebselen is an organoselenium compound that has shown promising activity as an antioxidant, anti-inflammatory, and neuroprotective agent. It has been investigated for its potential therapeutic applications in various conditions, including stroke, Alzheimer's disease, and cancer. Ebselen is synthesized through a multi-step process that involves the reaction of 2-nitrobenzenesulfonyl chloride with selenium dioxide. Its unique properties stem from the presence of the selenium atom, which allows it to effectively scavenge reactive oxygen species (ROS) and reduce oxidative stress. Ebselen has been shown to protect cells from damage caused by free radicals, inflammation, and apoptosis. Moreover, it has exhibited anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines. The potential benefits of ebselen in neurological disorders have been attributed to its ability to improve neuronal survival, reduce neuroinflammation, and promote axonal regeneration. The ongoing research on ebselen focuses on optimizing its delivery and bioavailability, exploring its therapeutic applications in a broader range of diseases, and understanding its molecular mechanisms of action. The potential of ebselen as a drug candidate has generated significant interest in the scientific community.'

ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3194
CHEMBL ID51085
CHEBI ID77543
SCHEMBL ID33829
MeSH IDM0126698

Synonyms (181)

Synonym
AC-1124 ,
MLS001148646 ,
HMS3394N09
BRD-K29359156-001-06-1 ,
MLS000028488 ,
KBIO1_000951 ,
DIVK1C_000951 ,
spi-3005
spi-1005
pz-51
dr-3305
harmokisane
nsc-639762
EU-0100541 ,
ebselen, cysteine modifier
E3520_SIGMA ,
IDI1_000951 ,
SPECTRUM5_001713 ,
c13h9nose
1,2-benzisoselenazol-3(2h)-one, 2-phenyl-
ebselene [french]
ebseleno [spanish]
ebselenum [latin]
2-phenyl-1,2-benzisoselenazolin-3-one
ebselen [inn]
ccris 3714
pz 51
dr 3305
2-phenyl-1,2-benzoisoselenazol-3(2h)-one
rp 60931
LS-33527 ,
nsc 639762
PRESTWICK_1057 ,
cas-60940-34-3
lopac-e-3520
BIO2_000542 ,
BIO2_000062 ,
NCGC00015412-02 ,
NCGC00015412-01 ,
BPBIO1_000770 ,
IDI1_033812 ,
PRESTWICK3_000740 ,
BSPBIO_000700 ,
NCGC00178610-01 ,
NCGC00178610-02 ,
NCGC00178610-03 ,
BCBCMAP01_000149 ,
BSPBIO_002538 ,
LOPAC0_000541 ,
MLS-0003066.0001 ,
AB00053217 ,
ebselen
2-phenyl-1,2-benzoselenazol-3-one
nsc639762
60940-34-3
2-phenyl-1,2-benzisoselenazol-3(2h)-one
SAM001247071 ,
cpd000058445 ,
cid3194
PRESTWICK2_000740 ,
NCGC00024072-05 ,
pz51
smr000058445
KBIO2_002630 ,
KBIO3_000123 ,
KBIO2_005198 ,
KBIOGR_000830 ,
KBIOSS_000062 ,
KBIO2_000062 ,
KBIO3_001758 ,
KBIOGR_000062 ,
KBIO3_000124 ,
PRESTWICK0_000740 ,
SPBIO_002639 ,
SPBIO_001301 ,
SPECTRUM2_001441 ,
PRESTWICK1_000740 ,
SPECTRUM3_000799 ,
SPECTRUM4_000445 ,
NINDS_000951 ,
BSPBIO_001342 ,
QTL1_000035 ,
NCGC00024072-03 ,
NCGC00015412-03 ,
NCHEMBIO.109-COMP1 ,
NCGC00024072-04 ,
spi1005
dr3305
C042986 ,
NCGC00015412-06 ,
E 3520 ,
HMS2052N09 ,
HMS1989D04 ,
NCGC00015412-13 ,
I09-1611 ,
chebi:77543 ,
CHEMBL51085 ,
nsc-757883
HMS502P13 ,
HMS1791D04 ,
HMS1361D04 ,
HMS1570C22 ,
AC1L1FDW ,
HMS2097C22
BRD-K29359156-001-23-6
nsc757883
MLS001424261
pharmakon1600-01501188
dtxsid7045150 ,
tox21_110140
dtxcid5025150
2-phenyl-1,2-benzoselenazol-3(2h)-one
HMS2235A11
CCG-39161 ,
NCGC00015412-10
NCGC00015412-12
NCGC00015412-09
NCGC00015412-04
NCGC00015412-07
NCGC00015412-11
NCGC00015412-05
NCGC00015412-08
SR-01000003081-10
sr-01000003081
ebselene
ebselenum
40x2p7dpgh ,
unii-40x2p7dpgh
ebseleno
LP00541
ksc-325-014
KUC112559N
AKOS015898841
S6676
MLS006010108
NC00431
E0946
SCHEMBL33829
phenyl-1,2-benzisoselenazol-3(2h)-one
2-phenyl-1,2-benzoisoselenazole-3(2h)-one
2-phenyl-1,2-benzoisoselenazole-3-(2h)-one
2-phenyl-1,2-benzisoselenazole-3(2h)-one
ebselen [mart.]
ebselen [jan]
ebselen [who-dd]
ebselen [mi]
2-phenyl-benzo[d]isoselenazol-3-one
ebselen (c5)
cid_3194
2-phenyl-1,2-benzisoselazol-3(2h)-one
bdbm34233
2-phenyl-benzo[d]isoselenazol-3-one(ebselen)
2-phenylbenzo[d][1,2]selenazol-3(2h)-one ,
dap001372
HB0270
HMS3649O05
HMS3402D04
OPERA_ID_1643
AB00053217_25
mfcd00210937
CS-5534
HY-13750
SR-01000003081-8
SR-01000003081-2
SR-01000003081-7
SBI-0050524.P003
HMS3714C22
DB12610
BCP17134
Q5332073
FT-0759332
EX-A1447
SR-01000003081-14
SDCCGSBI-0050524.P004
HMS3873N13
NCGC00015412-21
C75847
spi-1005;pz-51
gtpl10583
SY052687
A868855

Research Excerpts

Overview

Ebselen (SPI-1005) is an active selenoorganic compound that can be found potential inhibitory activity against different types of viral infections. Ebselen is a low-molecular-weight organoselenium compound that has been broadly studied for its antioxidant, anti-inflammatory, and cytoprotective properties.

ExcerptReferenceRelevance
"Ebselen is a relatively potent BBOX inhibitor, an observation which may in part reflect its cardioprotective properties."( Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
Benesch, JL; Brem, J; Kochan, GT; Rydzik, AM; Schofield, CJ; Struwe, WB, 2014
)
1.12
"Ebselen (SPI-1005) is an active selenoorganic compound that can be found potential inhibitory activity against different types of viral infections such as zika virus, influenza A virus, HCV, and HIV-1; and also be found to exhibit promising antiviral activity against SARS-CoV-2 in cell-based assays but its particular target action against specific non-structural and structural proteins of SARS-CoV-2 is unclear to date. "( Ebselen suitably interacts with the potential SARS-CoV-2 targets: an
Abdalla, M; Ali, N; Khalipha, ABR; Mondal, M; Sarkar, C, 2022
)
3.61
"Ebselen is an organic selenide that attenuates I/R injury in various organs."( Ebselen ameliorates renal ischemia-reperfusion injury via enhancing autophagy in rats.
Chen, W; Pei, J; Shi, H; Song, S; Wu, Y; Xu, S; Xu, Y, 2022
)
2.89
"Ebselen is a synthetic organoselenium compound which provides glutathione peroxidase-like activity."( Inhibition of H1N1 Influenza Virus-induced Apoptosis by Ebselen Through ROS-mediated ATM/ATR Signaling Pathways.
Chen, D; Chen, H; Lai, J; Li, Y; Liu, X; Ning, Z; Su, J; Zheng, R; Zhu, B, 2023
)
1.88
"Ebselen is a low-molecular-weight organoselenium compound that has been broadly studied for its antioxidant, anti-inflammatory, and cytoprotective properties. "( Antibacterial Activity of Ebselen.
Maślanka, M; Mucha, A, 2023
)
2.65
"Ebselen is an organoselenium compound exhibiting hydroperoxide- and peroxynitrite-reducing activity, acting as a glutathione peroxidase and peroxiredoxin enzyme mimetic. "( Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
Parnham, MJ; Sies, H, 2020
)
2.29
"Ebselen (EBS) is an organo-selenium-containing compound that has anti-inflammatory, antitumor, and antibacterial properties. "( Neuroprotective and Anti-neuroinflammatory Properties of Ebselen Derivatives and Their Potential to Inhibit Neurodegeneration.
Alaqel, S; Alsegiani, AS; Landgraf, AD; Shah, ZA; Sucheck, SJ; Thanna, S, 2020
)
2.25
"Ebselen is a synthetic organoselenium radical scavenger compound that possesses glutathione peroxidase-like activity and its own unique bioactivity by reacting with thiols, hydroperoxides and peroxynitrites. "( Mechanisms of ebselen as a therapeutic and its pharmacology applications.
Dong, C; Wang, J; Wang, P; Yuan, C; Zhao, Y; Zhou, J; Zou, L, 2020
)
2.36
"Ebselen, is an organoselenium compound, already successfully approved in clinical trials as a repositioned drug for the treatment of bipolar disorder and prevention of noise-induced hearing loss."( Efficacy of Ebselen Against Invasive Aspergillosis in a Murine Model.
Arita, GS; Becker, TCA; Bonfim-Mendonça, PS; Capoci, IRG; Conrado, PCV; Faria, DR; Kioshima, ES; Rodrigues-Vendramini, FAV; Sakita, KM; Svidzinski, TIE, 2021
)
1.72
"Ebselen is a potent competitive inhibitor of the active form of rabbit 15-lipoxygenase, an enzyme involved in many inflammatory diseases. "( Inhibition of Mammalian 15-Lipoxygenase by Three Ebselen-like Drugs. A QM/MM and MM/PBSA Comparative Study.
Cebrián-Prats, A; González-Lafont, À; Lluch, JM; Rovira, T; Saura, P, 2017
)
2.15
"Ebselen is a seleno-organic compound that has been demonstrated to have antioxidant and anti-inflammatory properties. "( Ebselen suppresses inflammation induced by Helicobacter pylori lipopolysaccharide via the p38 mitogen-activated protein kinase signaling pathway.
Gong, C; Li, G; Meng, W; Shi, M; Wang, T; Wang, Y; Wei, J; Xu, L, 2018
)
3.37
"Ebselen is a fat-soluble small molecule and organic selenium compound that regulates the activity of glutathione peroxidase to alleviate mitochondrial oxidative stress and improve mitochondrial function. "( Ebselen protects mitochondrial function and oxidative stress while inhibiting the mitochondrial apoptosis pathway after acute spinal cord injury.
Gao, ZY; He, XJ; Jia, ZQ; Li, SQ; Liu, JT; Qiao, WQ; Song, H; Xing, BW; Xing, JW; Xu, WZ, 2018
)
3.37
"Ebselen (Eb) is an example of a repurposed drug with poor aqueous solubility which requires sophisticated delivery system such as nanoencapsulation in nanocapsules for topical application."( Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity.
Andes, DR; Gubernator, J; Jaromin, A; Piętka-Ottlik, M; Zarnowski, R, 2018
)
2.25
"Ebselen is a seleno-organic compound that causes cell death in several cancer cell types. "( The seleno-organic compound ebselen impairs mitochondrial physiology and induces cell death in AR42J cells.
Fernandez-Bermejo, M; Garcia-Sanchez, L; Gonzalez, A; Ruy, DC; Salido, GM; Santofimia-Castaño, P, 2014
)
2.14
"Ebselen is a synthetic organoselenium compound that has been considered a potential pharmacological agent with low toxicity, showing antioxidant, anti-inflammatory and neuroprotective effects. "( Inhibitory effect of ebselen on cerebral acetylcholinesterase activity in vitro: kinetics and reversibility of inhibition.
Bruning, CA; Martini, F; Nogueira, CW; Soares, SM; Zeni, G, 2015
)
2.18
"Ebselen is an organoselenium compound which has strong antioxidant and anti-inflammatory effects. "( Different dose-dependent effects of ebselen in sciatic nerve ischemia-reperfusion injury in rats.
Akcer, S; Genc, O; Kocak, A; Kocak, C; Kocak, FE; Kucuk, A; Metineren, H; Ozyigit, F; Tosun, M, 2015
)
2.13
"Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties that is currently being examined in clinical trials to prevent and treat various diseases, including atherosclerosis, stroke, and cancer. "( Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek, JM; Kim, JY; Lee, MS; Oh, J; Yoon, KH, 2016
)
3.32
"Ebselen is an organoselenium compound with glutathione peroxidase (GPx)-like hydroperoxide reducing activity. "( Ebselen, a useful tool for understanding cellular redox biology and a promising drug candidate for use in human diseases.
Noguchi, N, 2016
)
3.32
"Ebselen is a glutathione peroxidase mimetic."( Ebselen does not improve oxidative stress and vascular function in patients with diabetes: a randomized, crossover trial.
Beckman, JA; Creager, MA; Goldfine, AB; Leopold, JA, 2016
)
2.6
"Ebselen is a seleno compound whose antioxidant properties have been attributed to its thiol-peroxidase and thioredoxin-like activity. "( Inhibitory effect of ebselen on lactate dehydrogenase activity from mammals: a comparative study with diphenyl diselenide and diphenyl ditelluride.
Lugokenski, TH; Müller, LG; Pereira, ME; Rocha, JB; Taube, PS, 2011
)
2.13
"Ebselen is a mimic of glutathione peroxidase that reacts with peroxynitrite and inhibits nitric oxide (NO) synthase. "( Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide.
Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011
)
2.11
"Ebselen is a seleno-compound used in the treatment of neurological disorders involving the glutamatergic system. "( Intrahippocampal infusion of ebselen impairs retention of an inhibitory avoidance task in rats.
Coitinho, AS; Izquierdo, I; Porciúncula, LO; Rocha, JB; Schmidt, AP; Souza, DO; Vinadé, L, 2002
)
2.05
"Ebselen is a seleno-organic compound that inhibits oxidative stress by lipid peroxidation through a glutathione peroxidase-like activity. "( Ebselen protects against the reduction in levels of drug-metabolizing enzymes in livers of rats with deoxycholic acid-induced liver injury.
Kobayashi, S; Kumai, T; Matsumoto, N; Nakaya, S; Takezawa, N; Tanaka, M; Watanabe, M, 2002
)
3.2
"Ebselen is a seleno organic compound with antioxidant and anti-inflammatory properties, which is under clinical trials for the treatment of ischemic stroke. "( Neuroprotective effect of ebselen on rat hippocampal slices submitted to oxygen-glucose deprivation: correlation with immunocontent of inducible nitric oxide synthase.
Cimarosti, H; Ghisleni, G; Porciúncula, LO; Rocha, JB; Salbego, CG; Souza, DO; Vinadé, L, 2003
)
2.06
"Ebselen is a selanazal drug recently revealed as a highly efficient peroxiredoxin mimic catalyzing the hydroperoxide reduction by the mammalian thioredoxin system [thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH]. "( Ebselen is a dehydroascorbate reductase mimic, facilitating the recycling of ascorbate via mammalian thioredoxin systems.
Holmgren, A; Zhao, R, 2004
)
3.21
"Ebselen is a seleno-organic compound that possesses low toxicity and exhibits antioxidant, anti-inflammatory, anti-atherosclerotic, and cytoprotective properties."( The effect of ebselen on adenine nucleotide hydrolysis by platelets from adult rats.
Battastini, AM; Fürstenau, CR; Luisa Berti, S; Rücker, B; Sarkis, JJ; Spier, AP, 2004
)
1.41
"Ebselen is an organoselenium compound that acts as a glutathione peroxidase mimic. "( Ebselen augments its peroxidase activity by inducing nrf-2-dependent transcription.
Arteel, GE; Falkner, KC; Jeffries, JM; Tamasi, V, 2004
)
3.21
"Ebselen is a selenium organic compound, which has been shown to be a neuroprotective agent in brain disorders involving glutamate receptors. "( The effects of ebselen on [3H]glutamate uptake by synaptic vesicles from rat brain.
Ghisleni, G; Porciúncula, LO; Rocha, JB; Souza, DO; Tavares, RG, 2004
)
2.12
"Thus ebselen is an effective neuroprotective agent against acute focal ischaemic-reperfusion injury."( The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat.
Dawson, DA; Graham, DI; Macrae, IM; Masayasu, H, 1995
)
1.03
"Ebselen is a seleno-organic anti-inflammatory compound with glutathione peroxidase-like activity that has the unique characteristic of mediating the isomerization of 5-HETE and LTB4 to their biologically inactive trans isomers, both directly in fluid phase and indirectly through metabolic pathways in stimulated peripheral blood leukocytes. "( Ebselen is a specific inhibitor of LTB4-mediated migration of human neutrophils.
Issekutz, AC; Patrick, RA; Peters, PA, 1993
)
3.17
"Ebselen is an antioxidant drug with glutathione peroxidase-like activity and a proven neuroprotective action in stroke patients."( The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease.
Blanchard, V; Daniel, N; Imperato, A; Moussaoui, S; Obinu, MC; Reibaud, M, 2000
)
1.37
"Ebselen is a selenium compound that have glutathione peroxidase-like activity which is neuroprotective in acute stroke ischemia. "( Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons.
Boeck, CR; Porciúncula, LO; Rocha, JB; Souza, DO; Vendite, D, 2001
)
3.2
"Ebselen is a seleno-organic compound currently in clinical trials for the treatment of ischemic stroke and subarachnoid hemorrhage. "( The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site.
Aizenman, E; Du, S; Herin, GA, 2001
)
2.05
"Ebselen (EBS) is a seleno-organic compound with glutathione peroxidase-like activity which is neuroprotective in acute stroke ischemia. "( Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat.
Mello, CF; Rocha, JB; Rossato, JI; Rubin, MA; Zeni, G, 2002
)
3.2
"Ebselen is a seleno-organic compound with documented cytoprotective properties. "( The effects of ebselen on cisplatin and diethyldithiocarbamate (DDC) cytotoxicity in rat hippocampal astrocytes.
Hardej, D; Trombetta, LD, 2002
)
2.11
"Ebselen is a new anti-inflammatory drug with a wide spectrum of pharmacological activities. "( Ebselen inhibits contractile responses of guinea-pig parenchymal lung strips.
Bast, A; Leurs, R; Timmerman, H, 1990
)
3.16
"Ebselen is a novel organo-selenium compound which catalytically inactivates peroxides in vitro in a manner similar to that of glutathione peroxidase (GSH-Px). "( Ebselen: a new approach to the inhibition of peroxide-dependent inflammation.
Kuhl, P; Leyck, S; Parnham, MJ; Schalkwijk, J; van den Berg, WB, 1987
)
3.16
"Ebselen (PZ 51) is a selenoorganic compound with antioxidant and antiinflammatory properties, and its metabolism was studied in isolated perfused rat liver (hemoglobin-free, open system). "( A novel biologically active selenooorganic compound--VII. Biotransformation of ebselen in perfused rat liver.
Fischer, H; Gabriel, H; Müller, A; Römer, A; Sies, H; Terlinden, R, 1988
)
1.95
"Ebselen is a novel selenoorganic compound with antioxidant activity capable of conferring protection against oxidative challenge."( Antioxidant activity in cells and organs.
Sies, H, 1987
)
0.99

Effects

Ebselen has a wide spectrum of interesting therapeutic actions including antioxidant, cytoprotective, neuroprotective and anti-inflammatory activities. Ebselen was found to have an antiatherosclerotic and renoprotective effect.

Ebselen could reduce the incidence and severity of tobramycin-induced hearing loss. Ebselen has been tested in clinical trials for other disorders, enabling us to determine the effect of a blood-brain barrier-penetrant IMPase inhibitor on human central nervous system function.

ExcerptReferenceRelevance
"Ebselen has an antiatherosclerotic and renoprotective effect in a model of accelerated diabetic complications in the setting of enhanced oxidative stress. "( Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.
Chew, P; Cooper, ME; Coughlan, MT; de Haan, JB; Jandeleit-Dahm, KA; Pete, J; Rosenfeldt, F; Stefanovic, N; Thomas, MC; Yuen, DY, 2010
)
2.06
"Ebselen has a wide spectrum of interesting therapeutic actions including antioxidant, cytoprotective, neuroprotective and anti-inflammatory activities. "( Antioxidant and anti-mutagenic effects of ebselen in yeast and in cultured mammalian V79 cells.
Henriques, JA; Lobo, LA; Miorelli, ST; Moura, DJ; Rocha, JC; Rosa, RM; Saffi, J, 2008
)
2.05
"Ebselen has tremendous pharmacological importance for some diseases due to its antioxidant, antiapoptotic, and anti-inflammatory features."( Ebselen, an Active Seleno-Organic Compound, Alleviates Articular Cartilage Degeneration in a Rat Model of Knee Osteoarthritis.
Kaçmaz, F; Kalacı, A; Karaboğa, İ; Okuyan, HM; Yurtal, Z, 2023
)
3.07
"Ebselen has known anti-inflammatory properties and could reduce the incidence and severity of tobramycin-induced hearing loss."( Ebselen attenuates tobramycin-induced ototoxicity in mice.
Gu, R; Homan, J; Kil, J; Longenecker, RJ, 2021
)
2.79
"Ebselen has neuron-protective effects due to its antioxidant properties as shown by the decrease in MDA overproduction, increase in SOD activity and the histological improvement after administration of Ebselen to I/R in brain tissue."( Effects of ebselen on ischemia/reperfusion injury in rat brain.
Altaş, M; Aras, M; Karcıoğlu, M; Meydan, S; Nacar, E; Serarslan, Y; Ulutaş, KT, 2014
)
2.23
"As ebselen has been shown to have significant cellular toxicity, appropriate studies are needed to redesign the ebselen-based therapy for clinical trials."( Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.
Azad, GK; Tomar, RS, 2014
)
2.36
"Ebselen has been tested in clinical trials for other disorders, enabling us to determine for the first time the effect of a blood-brain barrier-penetrant IMPase inhibitor on human central nervous system (CNS) function."( Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-Inositol, Sleep, and Emotional Processing in Humans.
Churchill, GC; Cowen, PJ; Emir, UE; Gluck, MA; Harmer, CJ; Herzallah, MM; Masaki, C; Sharp, T; Sharpley, AL; Singh, N; Vasudevan, SR, 2016
)
1.42
"Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown in vivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung."( Ebselen improves ischemia-reperfusion injury after rat lung transplantation.
Hamacher, J; Lucas, R; Stammberger, U; Weber, E; Wendel, A,
)
2.3
"Ebselen has an antiatherosclerotic and renoprotective effect in a model of accelerated diabetic complications in the setting of enhanced oxidative stress. "( Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.
Chew, P; Cooper, ME; Coughlan, MT; de Haan, JB; Jandeleit-Dahm, KA; Pete, J; Rosenfeldt, F; Stefanovic, N; Thomas, MC; Yuen, DY, 2010
)
2.06
"Ebselen has beneficial effects on the neurological outcome of patients with stroke."( Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide.
Fujisawa, H; Koizumi, H; Shirao, S; Suehiro, E; Suzuki, M, 2011
)
1.39
"Ebselen has a wide spectrum of interesting therapeutic actions including antioxidant, cytoprotective, neuroprotective and anti-inflammatory activities. "( Antioxidant and anti-mutagenic effects of ebselen in yeast and in cultured mammalian V79 cells.
Henriques, JA; Lobo, LA; Miorelli, ST; Moura, DJ; Rocha, JC; Rosa, RM; Saffi, J, 2008
)
2.05
"Ebselen also has properties such as free radical and singlet oxygen quenching."( Ebselen, a selenoorganic compound as glutathione peroxidase mimic.
Sies, H, 1993
)
2.45

Actions

Ebselen is known to catalyze glutathione peroxidase-like reactions and to inhibit lipid peroxidation. Ebselen reversed the increase in the hepatic GST activity of STZ-injected mice.

ExcerptReferenceRelevance
"Ebselen reversed the increase in the hepatic GST activity of the STZ-injected mice."( Ebselen reversed peripheral oxidative stress induced by a mouse model of sporadic Alzheimer's disease.
Klann, IP; Martini, F; Nogueira, CW; Rosa, SG, 2020
)
2.72
"Ebselen prevented the increase in nitrite production by human islets exposed for 14 hr to a combination of cytokines (IL-1 beta, tumor necrosis factor-alpha and interferon-gamma)."( Ebselen and cytokine-induced nitric oxide synthase expression in insulin-producing cells.
de-Mello, MA; Eizirik, DL; Flodström, M, 1996
)
2.46
"Ebselen is known to catalyze glutathione peroxidase-like reactions and to inhibit lipid peroxidation."( Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis.
Ferrell, LD; Grendell, JH; Lüthen, R; Niederau, C; Niederau, M; Strohmeyer, G; Ude, K, 1991
)
1.27

Treatment

Ebselen treatment significantly reduced the formation of hepatic AFB(1)-DNA adducts and 8-hydroxydeoxyguanosine. Ebselen pretreatment did not significantly increase viability in cells exposed to DDC.

ExcerptReferenceRelevance
"Ebselen pre-treatment blocked morphine's ability to upregulate FHC protein, suggesting this pathway requires DMT1 iron transport from endolysosomes."( The Endolysosomal Transporter DMT1 is Required for Morphine Regulation of Neuronal Ferritin Heavy Chain.
Brandimarti, R; Irollo, E; Luchetta, J; Meucci, O; Nash, B, 2023
)
1.63
"Ebselen co-treatment at 1:20 concentrations resulted in significant otoprotection."( Ebselen attenuates tobramycin-induced ototoxicity in mice.
Gu, R; Homan, J; Kil, J; Longenecker, RJ, 2021
)
2.79
"Ebselen treatment reversed the CS-induced reduction in colonic diameter."( Ebselen prevents cigarette smoke-induced gastrointestinal dysfunction in mice.
Balasuriya, GK; Brassington, K; Chan, SMH; De Luca, SN; Dobric, A; Herath, M; Hill-Yardin, EL; Lee, CYQ; Mohsenipour, M; Mou, K; Seow, HJ; Vlahos, R, 2020
)
2.72
"Ebselen treatment was well tolerated across all doses and no significant differences were seen in any haematological, serum chemistry, or radiological assessments between the ebselen groups and the placebo group."( Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial.
Antonelli, PJ; Griffiths, SK; Kil, J; Le Prell, CG; Lobarinas, E; Lynch, ED; Spankovich, C, 2017
)
1.49
"Ebselen treatment significantly ameliorated the neurological injury of TBI rats in a dose-dependent manner."( Neuroprotective effects of ebselen in traumatic brain injury model: involvement of nitric oxide and p38 mitogen-activated protein kinase signalling pathway.
Sun, Z; Wang, Q; Wei, L; Yang, C; Zhang, Y; Zhuang, Z, 2014
)
1.42
"Ebselen treatment of pancreatic and renal cancer cell lines stalled tumor growth and inhibited invasion through Matrigel in vitro."( Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines.
Borges, CR; Faigel, DO; Hanavan, PD; Ho, TH; Katchman, BA; Lake, DF; Ma, CT; Meurice, N; Petit, JL; Sergienko, EA, 2015
)
2.58
"Ebselen pretreatment also significantly suppressed cisplatin-induced increases in intracellular reactive oxygen species (ROS), intracellular reactive nitrogen species (RNS) and lipid peroxidation levels."( Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells.
Chung, SY; Han, AL; Kim, ES; Kim, HJ; Kim, JK; Kim, SJ; Kim, Y; Lee, HK; Lee, JH; Park, C; Park, R; So, H; Youn, MJ, 2009
)
2.52
"All ebselen-treated animals presented significant threshold elevations."( Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model.
Campbell, KC; Giordano, P; Hatzopoulos, S; Kochanek, K; Laurell, G; Lorito, G; Martini, A; Petruccelli, J; Skarzynski, H; Sliwa, L, 2011
)
0.85
"Ebselen was the only treatment able to decrease MDA concentration to control values, exerting an effect similar to that elicited by L-NAME on the rest of the parameters tested."( Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen.
Bosch-Morell, F; Díaz-Llopis, M; Johnsen-Soriano, S; Marín, N; Rodriguez-Galietero, A; Romá, J; Romero, B; Romero, FJ, 2002
)
1.25
"In ebselen-treated rats, the extent of tissue immunopositive for 8-oxodGuo, and 4-HNE was less than that demonstrating ischemic damage confirming the antioxidant mechanism of action in vivo."( Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia.
Graham, DI; Imai, H; Macrae, IM; Masayasu, H, 2003
)
1.21
"In ebselen-pretreated animals (30 mg/kg ip), venular thrombus formation was significantly delayed (50% vessel occlusion: 535+/-34 s; initial stasis: 872+/-82 s; complete occlusion: 908+/-87 s) as compared to vehicle-treated controls (416+/-42; 612+/-49; 647+/-51)."( Anti-oxidant ebselen delays microvascular thrombus formation in the rat cremaster muscle by inhibiting platelet P-selectin expression.
Belusa, L; Lindenblatt, N; Menger, MD; Nickels, RM; Schareck, W; Vollmar, B, 2003
)
1.2
"Ebselen treatments for 28 days decreased the elevated lipid peroxidation and also increased the reduced antioxidant enzyme levels."( Beneficial effects of Ebselen on corrosive esophageal burns of rats.
Coskun, O; Gurel, A; Hosnuter, M; Kanter, M; Ocakci, A; Tumkaya, L; Uzun, L, 2006
)
1.37
"Ebselen treatment restored the MDA and GSH concentrations and ERG b-wave amplitude to control values."( [Chronic ethanol feeding induces oxidative stress in the rat retina: treatment with the antioxidant ebselen].
Bosch-Morell, F; García-Delpech, S; Genovés, JM; Johnsen-Soriano, S; Muriach, M; Romero, B; Romero, FJ; Sancho-Tello, M, 2007
)
1.28
"Ebselen binds to untreated papain and to cysteine-treated papain at a ratio of about 0.1 and 0.75 mol ebselen/mol papain, respectively."( Interaction of ebselen with glutathione S-transferase and papain in vitro.
Nikawa, T; Schuch, G; Sies, H; Wagner, G, 1994
)
1.36
"Ebselen treatment resulted in a significant lowering of IL-6 plasma levels (26 +/- 5 pg/ml) as compared with that seen in lesioned vehicle controls (48 +/- 9 pg/ml) at 24 h postlesion."( Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia.
Arteel, GE; Bidmon, HJ; Divanach, A; Gladilin, S; Sies, H; Witte, OW; Zilles, K, 2000
)
2.47
"Ebselen treatment also caused a dose- and time-dependent loss of mitochondrial membrane potential (MMP) and release of cytochrome c."( Intracellular thiol depletion causes mitochondrial permeability transition in ebselen-induced apoptosis.
Ong, CN; Shen, HM; Yang, CF, 2000
)
1.26
"Ebselen treatment significantly reduced the formation of hepatic AFB(1)-DNA adducts and 8-hydroxydeoxyguanosine caused by AFB(1) exposure."( Inhibition of ebselen on aflatoxin B(1)-induced hepatocarcinogenesis in Fischer 344 rats.
Liu, J; Ong, CN; Shen, HM; Tan, CE; Wasser, S; Yang, CF, 2000
)
1.39
"Ebselen pretreatment had only a minor effect on malondialdehyde levels, whereas peroxide content was essentially abolished, suggesting that oxLDL-associated hydroperoxides may mediate both GSH depletion and gamma-GCS-HS induction."( OxLDL induces macrophage gamma-GCS-HS protein expression: a role for oxLDL-associated lipid hydroperoxide in GSH synthesis.
Sevanian, A; Shen, L, 2001
)
1.03
"Ebselen treatment diminished the cytochrome c release at 12 and 24 hours."( Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice.
Kikuchi, H; Masayasu, H; Nagata, I; Namura, S; Takami, S, 2001
)
2.47
"Ebselen pretreatment did not significantly increase viability in cells exposed to DDC."( The effects of ebselen on cisplatin and diethyldithiocarbamate (DDC) cytotoxicity in rat hippocampal astrocytes.
Hardej, D; Trombetta, LD, 2002
)
1.39
"Ebselen pretreatment inhibited neutrophil influx and activation as assessed by BAL fluid cellularity and myeloperoxidase activity in cell-free BAL and BAL cell homogenates."( Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation.
Belvisi, MG; Birrell, MA; Chen, B; Dabrowski, D; De Sanctis, GT; Foster, ML; Haddad, el-B; McCluskie, K; Pecoraro, M; Underwood, S; Webber, SE, 2002
)
1.34
"Treatment with ebselen and silver ion significantly reduced bacterial loads, down-regulated the expression levels of tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) on-site and decreased white/red blood cell counts in mild cystitis model mice, which demonstrated the anti-inflammatory property of these agents."( Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion.
Dong, C; Lu, Q; Wang, J; Wang, P; Xie, Z; Zhao, Y; Zhou, J; Zou, L, 2020
)
1.13
"Treatment with ebselen was safe and effective at a dose of 400 mg twice daily in preventing a noise-induced TTS. "( Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial.
Antonelli, PJ; Griffiths, SK; Kil, J; Le Prell, CG; Lobarinas, E; Lynch, ED; Spankovich, C, 2017
)
1.12
"Pretreatment with ebselen significantly improved serum AMH levels, relative to Groups 2 and 3."( Can ebselen prevent cisplatin-induced ovarian damage?
Bayindir, N; Boran, B; Esrefoglu, M; Soyman, Z; Uzun, H, 2018
)
1.36
"Treatment of ebselen markedly reduced the number of degenerating apoptotic neurons."( Neuroprotective effect of ebselen against intracerebroventricular streptozotocin-induced neuronal apoptosis and oxidative stress in rats.
Aktas, C; Albayrak, Y; Ates, O; Erboga, M; Oran, M; Ozen, OA; Topcu, B; Tulubas, F; Unsal, C; Uygur, R; Yanartas, O, 2016
)
1.09
"Pretreatment with ebselen prevented the death by 56% and attenuated neurological damage (abnormal eyelid drooping, hair bristling, muscle tone, flexor reflex, posture, and walking patterns)."( Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils.
Daily, JW; Kang, S; Kim, DS; Moon, NR; Park, S; Shin, BK, 2014
)
2.17
"Rats treated with Ebselen and exposed to CIH displayed a significant reduction in 3-NT-ir levels (60.8 ± 14.9 versus 22.9 ± 4.2 a.u.), reduced CB chemosensory response to 5% O2 (266.5 ± 13.4 versus 168.6 ± 16.8 Hz), and decreased mean BP (116.9 ± 13.2 versus 82.1 ± 5.1 mmHg)."( Intermittent Hypoxia-Induced Carotid Body Chemosensory Potentiation and Hypertension Are Critically Dependent on Peroxynitrite Formation.
Arias, P; Del Rio, R; Iturriaga, R; Moya, EA; Oyarce, MP; Varela, C, 2016
)
0.76
"Cotreatment with Ebselen and TNFalpha induced G2/M phase arrest in cell cycle and modulated the expression of molecules involved in cell cycle progression."( Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex.
Joseph, C; Sen, E; Sharma, V; Sk, UH; Tewari, R, 2008
)
2.12
"Pretreatment with ebselen ameliorated apoptotic death induced by cisplatin in HEI-OC1 cells and organotypic cultures of Corti's organ."( Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells.
Chung, SY; Han, AL; Kim, ES; Kim, HJ; Kim, JK; Kim, SJ; Kim, Y; Lee, HK; Lee, JH; Park, C; Park, R; So, H; Youn, MJ, 2009
)
2.12
"Treatment with Ebselen abrogated TNFalpha induced increase in pro-inflammatory mediators."( Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
Ghosh, A; Hossain Sk, U; Joseph, C; Koul, N; Sen, E; Sharma, V; Tewari, R, 2009
)
2.14
"Treatment with ebselen, a seleno-organic compound, effectively suppressed oxidative stress and protected cells against MeHg-induced relative selenium deficiency and cytotoxicity."( Post-transcriptional defects of antioxidant selenoenzymes cause oxidative stress under methylmercury exposure.
Fujimura, M; Usuki, F; Yamashita, A, 2011
)
0.71
"Pretreatment with ebselen, which induced significant (P < 0.05) increase in plasma selenium levels, did not significantly alter the decrease in reduced glutathione levels."( Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia.
Alborch, E; Burguete, MC; Marín, N; Pérez-Asensio, FJ; Pitarch, C; Romero, FJ; Salom, JB; Torregrosa, G, 2004
)
1.03
"Treatment with Ebselen partially prevented the decrease in capillary density and angiogenic competence of renal explants, and restored acetylcholine-induced vasorelaxation in 22-week-old ZDF rats."( Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen.
Brodsky, SV; Chander, PN; Friedli, C; Gealekman, O; Goligorsky, MS; Nasjletti, A; Zhang, F, 2004
)
0.88
"Treatment with Ebselen decreased tissue hydroxyproline levels, histological damage, and the stenosis index."( Beneficial effects of Ebselen on corrosive esophageal burns of rats.
Coskun, O; Gurel, A; Hosnuter, M; Kanter, M; Ocakci, A; Tumkaya, L; Uzun, L, 2006
)
0.99
"Pretreatment with ebselen at moderate doses (4-12 microM), but not at lower or higher doses, significantly improved glutamate-induced suppression of cell viability."( Neuroprotective effects of ebselen are associated with the regulation of Bcl-2 and Bax proteins in cultured mouse cortical neurons.
Hu, HT; Liu, Y; Liu, ZH; Qian, YH; Tan, QR; Xu, JH; Zhang, ZJ, 2006
)
0.95
"Treatment with ebselen, especially at concentrations of 20 and 40 microM prevented ischemia-induced cytotoxicity."( Ebselen attenuates oxidative stress in ischemic astrocytes depleted of glutathione. Comparison with glutathione precursors.
Gabryel, B; Małecki, A,
)
1.91
"Treatment with ebselen (4 mg/kg p.o.) before and immediately after noise exposure reduced both OHC loss and the swelling of the stria vascularis typically observed within 5h post-noise exposure."( Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase.
Gu, R; Kil, J; Lynch, ED; Pierce, C; Tran, H, 2007
)
2.12
"Pretreatment with ebselen (30 and 100 mg/kg, oral) significantly prevented this gastric mucosal injury and, further, remarkably decreased the elevated lipid peroxide and peptidoleukotriene levels."( Ebselen, a seleno-organic compound, protects against ethanol-induced murine gastric mucosal injury in both in vivo and in vitro systems.
Furuhama, K; Furusawa, M; Horiuchi, T; Sugiyama, N; Tabuchi, Y, 1995
)
2.06
"Pretreatment with ebselen (10 or 30 mg/kg p.o., 40 min pre-MCA occlusion) dose dependently reduced the volume of ischaemic damage assessed 4 h post-endothelin-1 application in the anesthetised rat."( The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat.
Dawson, DA; Graham, DI; Macrae, IM; Masayasu, H, 1995
)
0.9
"Pretreatment with ebselen increased the expression of such stress proteins as heat shock protein 70 and heme oxygenase-1 (heat shock protein 32) in cardiac myocytes, as assessed by Western blotting."( Effects of preconditioning with ebselen on glutathione metabolism and stress protein expression.
Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Nishida, M; Tada, M; Yamashita, N, 1997
)
0.9
"Treatment with ebselen (10 mg/kg) significantly decreased pulmonary inflammation as indicated by the albumin concentration and the number of neutrophils in the bronchoalveolar lavage fluid 18 h after the ozone exposure."( Ebselen decreases ozone-induced pulmonary inflammation in rats.
Hashimoto, K; Hirano, K; Ishii, Y; Masuyama, K; Mochizuki, M; Morishima, Y; Nomura, A; Sagai, M; Sakamoto, T; Sekizawa, K; Uchida, Y, 2000
)
2.09
"Treatment with ebselen reduced steady-state levels of transforming growth factor-beta1, procollagen I and III, tissue inhibitor of metalloproteinase-1, cytochrome P4502E1 and placental form glutathione-S-transferase transcripts, and increased transcripts of matrix metalloproteinase-13."( Anti-oxidant ebselen causes the resolution of experimentally induced hepatic fibrosis in rats.
Lim, GY; Ong, CN; Tan, CE; Wasser, S, 2001
)
1.02
"Treatment with ebselen did not reduce the antitumor activity of cisplatin against MPC 11 plasmacytoma or Prima breast tumor in BALB/c mice."( Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew, GS; de Goeij, JJ; Los, G; McVie, JG; van der Valk, MA; Vermeulen, NP, 1990
)
0.85
"Pretreatment with ebselen at oral doses from 10 to 100 mg/kg significantly inhibited such lesion formation induced by either necrotizing agent in a dose-related manner, and the inhibition at the highest dose (100 mg/kg p.o.) was practically complete."( Gastric cytoprotection by ebselen against the injury induced by necrotizing agents in rats.
Akasaki, M; Kurebayashi, Y; Tabuchi, Y, 1989
)
0.9

Toxicity

Treatment with ebselen was safe and effective at a dose of 400 mg twice daily in preventing a noise-induced TTS.

ExcerptReferenceRelevance
" However, this reduction of cisplatin-induced nephrotoxicity would be of little clinical value if it was achieved at toxic doses of ebselen."( Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew, GS; de Goeij, JJ; Los, G; McVie, JG; van der Valk, MA; Vermeulen, NP, 1990
)
0.71
" Here we report the potential toxic effects of diphenyl diselenide (PhSe)(2), diphenyl ditelluride (PhTe)(2) and Ebselen in rats and mice."( Potential renal and hepatic toxicity of diphenyl diselenide, diphenyl ditelluride and Ebselen for rats and mice.
Borges, VC; Meotti, FC; Nogueira, CW; Rocha, JB; Zeni, G, 2003
)
0.75
"Cisplatin ototoxicity has been associated with the generation of toxic levels of reactive oxygen species (ROS) which can lead to injury or loss of outer hair cells in the organ of Corti, damage to the stria vascularis, and loss of spiral ganglion cells, resulting in permanent hearing loss."( Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
Gu, R; Kil, J; Lynch, ED; Pierce, C, 2005
)
0.54
"The protective effect of ebselen, with documented glutathione peroxidase-like activity and antioxidative and anti-inflammatory properties, on the cytotoxicity induced by oxysterol was investigated in ECV-304 cells with cholestane-3beta, 5alpha, 6beta-triol (3-triol), one of the most toxic oxysterols."( Protective effect of ebselen on cytotoxicity induced by cholestane-3 beta, 5 alpha, 6 beta-triol in ECV-304 cells.
Huang, K; Wu, Q, 2006
)
0.96
" While generally less toxic than sulfur mustards, these compounds have the potential for use as chemical warfare agents."( Ebselen protects brain, skin, lung and blood cells from mechlorethamine toxicity.
Billack, B; Hardej, D, 2007
)
1.78
"Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects."( A safe lithium mimetic for bipolar disorder.
Aley, PK; Antoniadou, I; Baldwin, R; Churchill, GC; Halliday, AC; Kuznetsova, OV; Sharp, T; Singh, N; Thomas, JM; Vasudevan, SR; Woon, EC, 2013
)
0.39
" Following a 24-hour incubation of a toxic concentration of CEES (1000 μmol L-1), we used the MTT [3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide] test to analyse cell viability."( Ebselen analogues reduce 2-chloroethyl ethyl sulphide toxicity in A-431 cells.
Billack, B; Pietka-Ottlik, M; Pino, MA, 2013
)
1.83
"Treatment with ebselen was safe and effective at a dose of 400 mg twice daily in preventing a noise-induced TTS."( Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial.
Antonelli, PJ; Griffiths, SK; Kil, J; Le Prell, CG; Lobarinas, E; Lynch, ED; Spankovich, C, 2017
)
1.12
" Mercury is a toxic metal, widespread in the environment."( Chemical Speciation of Selenium and Mercury as Determinant of Their Neurotoxicity.
Aschner, M; Oliveira, CS; Piccoli, BC; Rocha, JBT, 2017
)
0.46
" Unfortunately, a common side effect is hearing loss, which can fluctuate."( Ebselen attenuates tobramycin-induced ototoxicity in mice.
Gu, R; Homan, J; Kil, J; Longenecker, RJ, 2021
)
2.06
"Arsenic (As) exposure is associated with adverse health outcomes to the living organisms."( Protective efficacy of thymoquinone or ebselen separately against arsenic-induced hepatotoxicity in rat.
Abdel Moneim, AE; Al Aboud, D; Alsharif, KF; Amin, HK; Baty, RS; Elmahallawy, EK; Habotta, OA; Hassan, KE; Kassab, RB; Zhery, AS, 2021
)
0.89

Compound-Compound Interactions

Study evaluated susceptibility of Trichosporon asahii strains to diphenyl diselenide (DPDS) and ebselen (EBS) using the microdilution method.

ExcerptReferenceRelevance
"Herein, we describe the in vitro activity of a combination of the organoselenium compounds diphenyl diselenide and ebselen alone and in combination with amphotericin B, caspofungin, itraconazole, and voriconazole against 25 clinical isolates of Fusarium spp."( Antifungal activities of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Fusarium spp.
Alves, SH; Azevedo, MI; Chassot, F; Keller, JT; Loreto, ÉS; Santurio, JM; Venturini, TP; Zeni, G, 2016
)
0.9
" Drug combination assays indicated that these derivatives exhibited synergistic antimicrobial activity when used along with meropenem, effectively restoring the activity of carbapenems against the resistant strains tested in a Galleria mellonella larvae in vivo infection model."( Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
Chan, EWC; Chan, KF; Chan, TH; Chen, S; Cheng, Q; Gao, W; Jin, WB; Leung, YC; Qi, XL; Wong, KY; Xu, C; Zheng, Z, 2018
)
0.48
"This study evaluated the in vitro susceptibility of Trichosporon asahii strains to diphenyl diselenide (DPDS) and ebselen (EBS) alone and in combination with amphotericin B (AMB), fluconazole (FCZ), itraconazole (ITZ) and caspofungin (CAS) using the microdilution method."( In vitro activity of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Trichosporon asahii.
Bedin Denardi, L; Felli Kubiça, T; Hartz Alves, S; Morais Santurio, J; Oliveira, V; Silva de Loreto, É; Weiblen, C; Zeni, G, 2019
)
0.98

Bioavailability

ExcerptReferenceRelevance
" However, these drugs have poor bioavailability and a number of side effects, including gastrointestinal upsets and hepatotoxicity."( Inhibitory effect of ebselen on cerebral acetylcholinesterase activity in vitro: kinetics and reversibility of inhibition.
Bruning, CA; Martini, F; Nogueira, CW; Soares, SM; Zeni, G, 2015
)
0.74
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Ebselen may be neuroprotective when administered shortly after an embolic stroke. Ebselen administration for 14 days at a daily dosage of 10 mg/kg provided substantial protection against killing and oxidative damage to mice exposed to whole-body irradiation.

ExcerptRelevanceReference
" The IFN and TNF response was rapid, occurring within 20 h, and high--up to 1000 and 2000 units ml-1--and was clearly related to the dosage and the structure of the compounds."( Organoselenides as potential immunostimulants and inducers of interferon gamma and other cytokines in human peripheral blood leukocytes.
Inglot, AD; Młochowski, J; Piasecki, E; Syper, L; Zielińska-Jenczylik, J, 1990
)
0.28
" The monkeys were randomly divided into three groups according to Ebselen dosage: 1) no dosage or non-treated group; 2) high-dose Ebselen group; and 3) low-dose Ebselen group."( Effect of an antioxidant, ebselen, on development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates.
Handa, Y; Kaneko, M; Kobayashi, H; Kubota, T; Takeuchi, H; Tsuchida, A, 2000
)
0.84
"This study indicates that ebselen may be neuroprotective when administered shortly after an embolic stroke, but the time- and dose-response analyses suggest that it has a narrow therapeutic window."( Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
Lapchak, PA; Zivin, JA, 2003
)
2.06
" Data from the permanent MCAO model and an embolic stroke model suggested a bell shaped dose-response curve."( Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Ashwood, T; Green, AR, 2005
)
0.33
" Ebselen administration for 14 days at a daily dosage of 10 mg/kg provided substantial protection against killing and oxidative damage to mice exposed to whole-body irradiation."( The use of ebselen for radioprotection in cultured cells and mice.
Park, JW; Tak, JK, 2009
)
1.65
"Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects."( A safe lithium mimetic for bipolar disorder.
Aley, PK; Antoniadou, I; Baldwin, R; Churchill, GC; Halliday, AC; Kuznetsova, OV; Sharp, T; Singh, N; Thomas, JM; Vasudevan, SR; Woon, EC, 2013
)
0.39
" Current evidence suggests that a more nuanced approach to antioxidant therapy is more likely to yield positive reductions in end-organ injury, with considerations required for the types of ROS/RNS involved, the timing and dosage of antioxidant therapy, and the selective targeting of cell populations."( Are reactive oxygen species still the basis for diabetic complications?
de Haan, JB; Di Marco, E; Jandeleit-Dahm, KA; Jha, JC; Sharma, A; Wilkinson-Berka, JL, 2015
)
0.42
"The study suggests that at the dosage used, ebselen can decrease impulsivity and produce a positive bias in emotional processing."( Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing.
Churchill, GC; Cooper, CM; Cowen, PJ; Godlewska, BR; Harmer, CJ; Masaki, C; Rogers, RD; Sharp, T; Sharpley, AL; Singh, N; Vasudevan, SR, 2016
)
0.96
"The results showed that the effective dosage of this combination was observed at 25 μg/ml of Ebs with γ-radiation at 6 Gy."( Synergistic effect of Ebselen and gamma radiation on breast cancer cells.
Moustafa, EM; Thabet, NM, 2017
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (23)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
anti-inflammatory drugA substance that reduces or suppresses inflammation.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
hepatoprotective agentAny compound that is able to prevent damage to the liver.
genotoxinA role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
enzyme mimicAny small molecule that mimics the action of an enzyme.
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitorAn EC 1.3.1.* (oxidoreductase acting on donor CH-CH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of acyl-CoA dehydrogenase (NADP(+)), EC 1.3.1.8.
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitorAn EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of trypanothione-disulfide reductase (EC 1.8.1.12).
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitorA lipoxygenase inhibitor that interferes with the action of arachidonate 15-lipoxygenase (EC 1.13.11.33).
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitorA lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7).
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitorAn EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1).
EC 3.5.4.1 (cytosine deaminase) inhibitorAn EC 3.5.4.* (non-peptide cyclic amidine C-N hydrolase) inhibitor that interferes with the action of cytosine deaminase (EC 3.5.4.1).
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitorAn EC 5.1.3.* (racemases acting on carbohydrates and derivatives) inhibitor that interferes with the action of UDP-glucose 4-epimerase (EC 5.1.3.2).
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitorAn EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69).
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitorAn EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of inositol-phosphate phosphatase (EC 3.1.3.25).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzoselenazoleAn organic heterobicyclic compound whose skeleton consists of a benzene ring which is ortho-fused to a selenzole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (180)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency14.33350.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.05760.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency57.12200.044717.8581100.0000AID485294; AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency22.66550.140911.194039.8107AID2451; AID2785; AID2787
Chain A, HADH2 proteinHomo sapiens (human)Potency2.15320.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency2.15320.025120.237639.8107AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency8.91250.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency2.65550.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency12.58935.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency28.18380.002014.677939.8107AID1478
LuciferasePhotinus pyralis (common eastern firefly)Potency17.12160.007215.758889.3584AID411; AID588342; AID624030
Nrf2Homo sapiens (human)Potency29.29530.09208.222223.1093AID624149; AID624171
glp-1 receptor, partialHomo sapiens (human)Potency14.12540.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency14.77150.100020.879379.4328AID588453; AID588456
RGS12Homo sapiens (human)Potency12.58930.794310.991425.1189AID879
15-lipoxygenase, partialHomo sapiens (human)Potency0.23060.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency2.63830.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID493107
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency12.58930.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency5.40250.35487.935539.8107AID624146; AID624170
TDP1 proteinHomo sapiens (human)Potency4.37870.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency3.59330.180013.557439.8107AID1460; AID1468
ThrombopoietinHomo sapiens (human)Potency3.16230.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency29.05220.000221.22318,912.5098AID743035; AID743042; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency44.66840.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency23.75300.00527.809829.0929AID588855
DNA polymerase III, partialBacillus subtilisPotency4.74441.062114.152826.6795AID485295
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.23060.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency17.55950.00137.762544.6684AID914; AID915
hypothetical protein, conservedTrypanosoma bruceiPotency11.14710.223911.245135.4813AID624147; AID624173; AID720569; AID720584
regulator of G-protein signaling 4Homo sapiens (human)Potency14.42700.531815.435837.6858AID504845
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency50.11876.309627.099079.4328AID602179
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency2.11540.28189.721235.4813AID2326
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.72730.000229.305416,493.5996AID743069; AID743075; AID743080; AID743091
glucocerebrosidaseHomo sapiens (human)Potency32.55970.01268.156944.6684AID2101
luciferasePhoturis pensylvanica (Pennsylania firefly)Potency18.07890.891310.432820.5750AID1379; AID2265; AID2530
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency1.41250.707936.904389.1251AID504333
alpha-galactosidaseHomo sapiens (human)Potency32.46484.466818.391635.4813AID957; AID998
pyruvate kinaseLeishmania mexicana mexicanaPotency15.55130.398113.744731.6228AID1721; AID1722; AID2559; AID945; AID959
IDH1Homo sapiens (human)Potency23.10930.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.74610.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency21.97430.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency5.50000.00207.533739.8107AID891
hexokinase-4 isoform 1Homo sapiens (human)Potency14.12542.511913.800328.1838AID743205
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency33.807823.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency7.94330.316212.443531.6228AID902
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency2.83711.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.85540.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.53970.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency22.38720.02245.944922.3872AID488981
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency0.56460.001815.663839.8107AID894
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency6.74560.134610.395030.1313AID1347049
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency8.90600.354828.065989.1251AID504847
fructose-bisphosphate aldolase AOryctolagus cuniculus (rabbit)Potency22.38720.891316.576239.8107AID2794
chromobox protein homolog 1Homo sapiens (human)Potency13.81540.006026.168889.1251AID488953; AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.82990.000323.4451159.6830AID743065; AID743067
glucokinase regulatory proteinHomo sapiens (human)Potency14.12542.511913.800328.1838AID743205
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1Homo sapiens (human)Potency12.58930.794312.126325.1189AID879
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
pyruvate kinase PKM isoform aHomo sapiens (human)Potency5.11890.04017.459031.6228AID1631; AID1634; AID2263; AID2267
DNA polymerase betaHomo sapiens (human)Potency3.16230.022421.010289.1251AID485314
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency26.12160.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency79.43280.133725.412989.1251AID588795
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency20.40540.00378.618923.2809AID2660; AID2668
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency2.99350.168316.404067.0158AID720504
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency44.66840.010323.856763.0957AID2662
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency0.00160.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.76280.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency19.30060.004611.374133.4983AID463097; AID504364; AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency28.69540.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency14.55000.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency4.00270.177824.735279.4328AID488949
transient receptor potential cation channel subfamily V member 1Homo sapiens (human)Potency31.62280.09120.09120.0912AID488979
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.44960.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.16810.020010.786931.6228AID912
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency35.48130.025911.239831.6228AID602313
lamin isoform A-delta10Homo sapiens (human)Potency0.00200.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency10.00002.511912.262825.1189AID954; AID958
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency0.56610.316212.765731.6228AID881
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
Sodium channel protein type 1 subunit alphaRattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
Sodium channel protein type 2 subunit alphaRattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
Sodium channel protein type 3 subunit alphaRattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Endothelin receptor type BRattus norvegicus (Norway rat)Potency22.38720.562315.160931.6228AID1721
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Endothelin-1 receptorRattus norvegicus (Norway rat)Potency22.38720.562315.160931.6228AID1721
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Potency5.79880.794312.269331.6228AID2263
Alpha-synucleinHomo sapiens (human)Potency4.47800.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.55030.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
TAR DNA-binding protein 43Homo sapiens (human)Potency6.30961.778316.208135.4813AID652104
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
GABA theta subunitRattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Potency5.79885.79886.27056.5064AID2263
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency14.55001.000012.224831.6228AID885
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Potency5.79885.79886.27056.5064AID2263
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency7.56867.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency5.83530.060110.745337.9330AID485367; AID485368; AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA polymerase beta subunit (EC 2.7.7.6), partialEscherichia coliIC50 (µMol)11.687211.687217.090023.7759AID826
Arrestin, beta 1Homo sapiens (human)IC50 (µMol)1.52401.52404.01608.8840AID588783
MPI proteinHomo sapiens (human)IC50 (µMol)0.29050.190013.825650.1000AID1220; AID1535
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonasePlasmodium bergheiIC50 (µMol)15.08670.889021.028671.5000AID504765; AID540252; AID540269
TPA: protein transporter TIM10Saccharomyces cerevisiae S288CIC50 (µMol)5.29000.580026.547675.8000AID493003; AID504542
TPA: protein transporter TIM23Saccharomyces cerevisiae S288CIC50 (µMol)0.88000.880010.503632.9000AID504544
hexokinaseTrypanosoma brucei brucei TREU927IC50 (µMol)0.90090.20084.602422.3780AID1632
Spike glycoproteinBetacoronavirus England 1IC50 (µMol)0.67000.03002.72839.5100AID1804127
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)5.33500.00403.43889.5100AID1640022; AID1804127
neutrophil cytosol factor 1Homo sapiens (human)IC50 (µMol)0.39000.39006.544129.1200AID1275
phosphomannomutase 2Homo sapiens (human)IC50 (µMol)0.67200.672034.783897.3000AID1655
perilipin-5Homo sapiens (human)IC50 (µMol)1.10100.98503.45659.4680AID504319
glucose-6-phosphate 1-dehydrogenase isoform bHomo sapiens (human)IC50 (µMol)13.20008.870012.851817.8000AID504792
phosphoethanolamine/phosphocholine phosphatase isoform 1Homo sapiens (human)IC50 (µMol)0.11100.11100.57690.9410AID1666
perilipin-1Homo sapiens (human)IC50 (µMol)3.41000.92503.30339.6190AID504317
eukaryotic translation initiation factor 4 gamma 1 isoform 4Homo sapiens (human)IC50 (µMol)1.15001.150012.620025.6529AID855
eukaryotic translation initiation factor 4E isoform 1Mus musculus (house mouse)IC50 (µMol)1.15001.150012.620025.6529AID855
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform aHomo sapiens (human)IC50 (µMol)2.25550.92503.58289.6190AID504317; AID504319
Sulfhydryl oxidase 1Homo sapiens (human)IC50 (µMol)5.40005.40005.40005.4000AID1527050
Transmembrane protease serine 2Homo sapiens (human)IC50 (µMol)0.67000.01802.61989.5100AID1804127
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)28.00500.00000.94539.9400AID1055219; AID1070084
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)2.10000.00051.41288.2000AID363800
Gamma-butyrobetaine dioxygenaseHomo sapiens (human)IC50 (µMol)0.74200.69003.16457.9000AID1166880; AID1166881; AID1166882; AID1166883; AID1166884
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.00000.11007.190310.0000AID1449628
Procathepsin LHomo sapiens (human)IC50 (µMol)0.67000.00021.66619.5100AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.67000.03002.29719.5100AID1804127
Replicase polyprotein 1abHuman coronavirus 229EIC50 (µMol)0.67000.03002.14419.5100AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.62000.00402.92669.9600AID1804127; AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.79280.00022.45859.9600AID1640021; AID1803933; AID1804127; AID1805801; AID1845234; AID1845236; AID1881720; AID1881722; AID1881726; AID1884045; AID1884557; AID1897971; AID1898064
Macrophage migration inhibitory factorHomo sapiens (human)IC50 (µMol)2.40000.03803.09109.8000AID1384614
Macrophage migration inhibitory factorHomo sapiens (human)Ki0.57000.03802.22565.5500AID1384615; AID1799792
Insulin-degrading enzymeHomo sapiens (human)IC50 (µMol)33.35200.01402.35207.0000AID1600069; AID1600086; AID1600088
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)Ki0.09400.09402.37907.0000AID1266394; AID1557399; AID1888015
Urease subunit alphaHelicobacter pylori 26695IC50 (µMol)30.47250.29003.87606.7000AID1632342; AID1632343; AID1632344; AID1632345
Urease subunit alphaHelicobacter pylori 26695Ki0.22600.22603.40579.3400AID1632341
Toxin BClostridioides difficileIC50 (µMol)0.01720.01720.01720.0172AID1527053
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)15.00000.00000.933210.0000AID1070082
Caspase-1Homo sapiens (human)IC50 (µMol)4.04000.00201.70138.8000AID1801388
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)0.75750.00000.54509.1000AID1615721; AID1615722; AID1615730; AID755348
Methionine aminopeptidase 2Homo sapiens (human)IC50 (µMol)2.43000.00060.96835.6000AID1322288
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.67000.03002.77319.5100AID1804127
Urease subunit betaHelicobacter pylori 26695IC50 (µMol)30.47250.29003.87606.7000AID1632342; AID1632343; AID1632344; AID1632345
Urease subunit betaHelicobacter pylori 26695Ki0.22600.22603.40579.3400AID1632341
CholinesteraseEquus caballus (horse)IC50 (µMol)10.47400.00002.22149.4000AID1055218; AID1070083
UDP-glucose 4-epimeraseHomo sapiens (human)IC50 (µMol)0.01400.01401.37133.6000AID276473
Structural capsid protein Human immunodeficiency virus 1IC50 (µMol)0.04670.04673.06568.9300AID1846327
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)IC50 (µMol)0.40000.00251.14809.2000AID1374899
Angiotensin-converting enzyme 2 Homo sapiens (human)IC50 (µMol)0.67000.00042.207910.0000AID1804127
Histone-lysine N-methyltransferase EHMT1Homo sapiens (human)IC50 (µMol)0.73000.01300.79954.9000AID1374900
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)6.53330.00000.53769.9000AID1418666; AID1527047; AID1527048
Histone deacetylase 9Homo sapiens (human)IC50 (µMol)3.70000.00050.94139.9000AID1527049
Histone deacetylase 5Homo sapiens (human)IC50 (µMol)3.40000.00070.961010.0000AID1527046
large T antigenBetapolyomavirus macacaeIC50 (µMol)13.91000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)4.67000.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)4.67000.00304.57559.8200AID1804127
hexokinase HKDC1Homo sapiens (human)EC50 (µMol)38.80000.21200.21200.2120AID504730
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)1.51900.06008.9128130.5170AID1902
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)4.67000.00304.51689.8200AID1804127
Gamma-butyrobetaine dioxygenaseHomo sapiens (human)Kd4.10003.60005.26677.6000AID1166891; AID1166892
Procathepsin LHomo sapiens (human)EC50 (µMol)4.67000.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)4.67000.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)4.67000.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)4.67000.00304.45549.8200AID1804127; AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)4.67000.00304.11059.8200AID1804127; AID1805801
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)4.67000.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)4.67000.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypothetical protein CAALFM_CR05890CACandida albicans SC5314AC501.55001.550013.003854.7000AID588764
H3 histone acetyltransferaseCandida albicans SC5314AC501.55001.550013.003854.7000AID588764
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (573)

Processvia Protein(s)Taxonomy
negative regulation of macroautophagySulfhydryl oxidase 1Homo sapiens (human)
extracellular matrix assemblySulfhydryl oxidase 1Homo sapiens (human)
protein foldingSulfhydryl oxidase 1Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
carnitine biosynthetic processGamma-butyrobetaine dioxygenaseHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
prostaglandin biosynthetic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cytokine productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of mature B cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
inflammatory responseMacrophage migration inhibitory factorHomo sapiens (human)
cell surface receptor signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of gene expressionMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of protein kinase A signalingMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of macrophage chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
carboxylic acid metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cell migrationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of B cell proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of tumor necrosis factor productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of myeloid cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
regulation of macrophage activationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
innate immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of fibroblast proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of protein metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of prostaglandin secretion involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
protein homotrimerizationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of arachidonic acid secretionMacrophage migration inhibitory factorHomo sapiens (human)
cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
superoxide anion generationNeutrophil cytosol factor 1Homo sapiens (human)
protein targeting to membraneNeutrophil cytosol factor 1Homo sapiens (human)
superoxide metabolic processNeutrophil cytosol factor 1Homo sapiens (human)
cellular defense responseNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to reactive oxygen speciesNeutrophil cytosol factor 1Homo sapiens (human)
superoxide anion generationNeutrophil cytosol factor 1Homo sapiens (human)
innate immune responseNeutrophil cytosol factor 1Homo sapiens (human)
respiratory burstNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of JNK cascadeNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNeutrophil cytosol factor 1Homo sapiens (human)
regulation of respiratory burst involved in inflammatory responseNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to cadmium ionNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to glucose stimulusNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to testosterone stimulusNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of p38MAPK cascadeNeutrophil cytosol factor 1Homo sapiens (human)
reactive oxygen species biosynthetic processNeutrophil cytosol factor 1Homo sapiens (human)
proteolysisInsulin-degrading enzymeHomo sapiens (human)
insulin receptor signaling pathwayInsulin-degrading enzymeHomo sapiens (human)
bradykinin catabolic processInsulin-degrading enzymeHomo sapiens (human)
ubiquitin recyclingInsulin-degrading enzymeHomo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IInsulin-degrading enzymeHomo sapiens (human)
protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
positive regulation of protein bindingInsulin-degrading enzymeHomo sapiens (human)
hormone catabolic processInsulin-degrading enzymeHomo sapiens (human)
peptide catabolic processInsulin-degrading enzymeHomo sapiens (human)
positive regulation of protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
symbiont entry into host cellInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta metabolic processInsulin-degrading enzymeHomo sapiens (human)
proteolysis involved in protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta clearanceInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta clearance by cellular catabolic processInsulin-degrading enzymeHomo sapiens (human)
insulin metabolic processInsulin-degrading enzymeHomo sapiens (human)
insulin catabolic processInsulin-degrading enzymeHomo sapiens (human)
regulation of aerobic respirationInsulin-degrading enzymeHomo sapiens (human)
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
protein processingMethionine aminopeptidase 2Homo sapiens (human)
peptidyl-methionine modificationMethionine aminopeptidase 2Homo sapiens (human)
N-terminal protein amino acid modificationMethionine aminopeptidase 2Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
galactose catabolic processUDP-glucose 4-epimeraseHomo sapiens (human)
galactose catabolic process via UDP-galactoseUDP-glucose 4-epimeraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to starvationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of DNA replicationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
synaptonemal complex assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
spermatid developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
long-term memoryHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
fertilizationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of protein modification processHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
organ growthHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
phenotypic switchingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
behavioral response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
oocyte developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
neuron fate specificationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to xenobiotic stimulusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of autophagosome assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
regulation of embryonic developmentHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of cytokine productionHistone deacetylase 9Homo sapiens (human)
response to amphetamineHistone deacetylase 9Homo sapiens (human)
inflammatory responseHistone deacetylase 9Homo sapiens (human)
heart developmentHistone deacetylase 9Homo sapiens (human)
neuron differentiationHistone deacetylase 9Homo sapiens (human)
B cell differentiationHistone deacetylase 9Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 9Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 9Homo sapiens (human)
B cell activationHistone deacetylase 9Homo sapiens (human)
cholesterol homeostasisHistone deacetylase 9Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 9Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 9Homo sapiens (human)
regulation of skeletal muscle fiber developmentHistone deacetylase 9Homo sapiens (human)
regulation of striated muscle cell differentiationHistone deacetylase 9Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
inflammatory responseHistone deacetylase 5Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 5Homo sapiens (human)
regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
response to activityHistone deacetylase 5Homo sapiens (human)
neuron differentiationHistone deacetylase 5Homo sapiens (human)
B cell differentiationHistone deacetylase 5Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 5Homo sapiens (human)
B cell activationHistone deacetylase 5Homo sapiens (human)
response to cocaineHistone deacetylase 5Homo sapiens (human)
regulation of protein bindingHistone deacetylase 5Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 5Homo sapiens (human)
cellular response to lipopolysaccharideHistone deacetylase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (180)

Processvia Protein(s)Taxonomy
protein disulfide isomerase activitySulfhydryl oxidase 1Homo sapiens (human)
flavin-dependent sulfhydryl oxidase activitySulfhydryl oxidase 1Homo sapiens (human)
FAD bindingSulfhydryl oxidase 1Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
iron ion bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
protein bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
zinc ion bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
gamma-butyrobetaine dioxygenase activityGamma-butyrobetaine dioxygenaseHomo sapiens (human)
identical protein bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protease bindingMacrophage migration inhibitory factorHomo sapiens (human)
dopachrome isomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine receptor bindingMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
chemoattractant activityMacrophage migration inhibitory factorHomo sapiens (human)
identical protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
phenylpyruvate tautomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingNeutrophil cytosol factor 1Homo sapiens (human)
electron transfer activityNeutrophil cytosol factor 1Homo sapiens (human)
superoxide-generating NAD(P)H oxidase activityNeutrophil cytosol factor 1Homo sapiens (human)
SH3 domain bindingNeutrophil cytosol factor 1Homo sapiens (human)
phosphatidylinositol bindingNeutrophil cytosol factor 1Homo sapiens (human)
phosphatidylinositol-3,4-bisphosphate bindingNeutrophil cytosol factor 1Homo sapiens (human)
superoxide-generating NADPH oxidase activator activityNeutrophil cytosol factor 1Homo sapiens (human)
virus receptor activityInsulin-degrading enzymeHomo sapiens (human)
endopeptidase activityInsulin-degrading enzymeHomo sapiens (human)
metalloendopeptidase activityInsulin-degrading enzymeHomo sapiens (human)
protein bindingInsulin-degrading enzymeHomo sapiens (human)
ATP bindingInsulin-degrading enzymeHomo sapiens (human)
zinc ion bindingInsulin-degrading enzymeHomo sapiens (human)
peptide bindingInsulin-degrading enzymeHomo sapiens (human)
protein homodimerization activityInsulin-degrading enzymeHomo sapiens (human)
insulin bindingInsulin-degrading enzymeHomo sapiens (human)
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA bindingMethionine aminopeptidase 2Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
initiator methionyl aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
protein bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloexopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
metal ion bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloaminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
UDP-N-acetylglucosamine 4-epimerase activityUDP-glucose 4-epimeraseHomo sapiens (human)
UDP-glucose 4-epimerase activityUDP-glucose 4-epimeraseHomo sapiens (human)
identical protein bindingUDP-glucose 4-epimeraseHomo sapiens (human)
protein homodimerization activityUDP-glucose 4-epimeraseHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
enzyme bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K56 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein kinase C bindingHistone deacetylase 9Homo sapiens (human)
protein bindingHistone deacetylase 9Homo sapiens (human)
histone H3K14 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H3K9 deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H4K16 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 9Homo sapiens (human)
metal ion bindingHistone deacetylase 9Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 5Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 5Homo sapiens (human)
chromatin bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase activityHistone deacetylase 5Homo sapiens (human)
protein kinase C bindingHistone deacetylase 5Homo sapiens (human)
protein bindingHistone deacetylase 5Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 5Homo sapiens (human)
identical protein bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 5Homo sapiens (human)
metal ion bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (134)

Processvia Protein(s)Taxonomy
Golgi membraneSulfhydryl oxidase 1Homo sapiens (human)
extracellular regionSulfhydryl oxidase 1Homo sapiens (human)
extracellular spaceSulfhydryl oxidase 1Homo sapiens (human)
endoplasmic reticulum lumenSulfhydryl oxidase 1Homo sapiens (human)
Golgi apparatusSulfhydryl oxidase 1Homo sapiens (human)
platelet alpha granule lumenSulfhydryl oxidase 1Homo sapiens (human)
specific granule lumenSulfhydryl oxidase 1Homo sapiens (human)
intracellular membrane-bounded organelleSulfhydryl oxidase 1Homo sapiens (human)
intercellular bridgeSulfhydryl oxidase 1Homo sapiens (human)
extracellular exosomeSulfhydryl oxidase 1Homo sapiens (human)
tertiary granule lumenSulfhydryl oxidase 1Homo sapiens (human)
extracellular spaceSulfhydryl oxidase 1Homo sapiens (human)
Golgi membraneSulfhydryl oxidase 1Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
cytosolGamma-butyrobetaine dioxygenaseHomo sapiens (human)
extracellular exosomeGamma-butyrobetaine dioxygenaseHomo sapiens (human)
mitochondrionGamma-butyrobetaine dioxygenaseHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
extracellular regionMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
nucleoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytosolMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneMacrophage migration inhibitory factorHomo sapiens (human)
cell surfaceMacrophage migration inhibitory factorHomo sapiens (human)
vesicleMacrophage migration inhibitory factorHomo sapiens (human)
secretory granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular exosomeMacrophage migration inhibitory factorHomo sapiens (human)
ficolin-1-rich granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
cytosolNeutrophil cytosol factor 1Homo sapiens (human)
plasma membraneNeutrophil cytosol factor 1Homo sapiens (human)
cytoplasmic side of plasma membraneNeutrophil cytosol factor 1Homo sapiens (human)
membraneNeutrophil cytosol factor 1Homo sapiens (human)
dendriteNeutrophil cytosol factor 1Homo sapiens (human)
phagolysosomeNeutrophil cytosol factor 1Homo sapiens (human)
NADPH oxidase complexNeutrophil cytosol factor 1Homo sapiens (human)
neuronal cell bodyNeutrophil cytosol factor 1Homo sapiens (human)
cytoplasmNeutrophil cytosol factor 1Homo sapiens (human)
nucleusInsulin-degrading enzymeHomo sapiens (human)
extracellular spaceInsulin-degrading enzymeHomo sapiens (human)
nucleusInsulin-degrading enzymeHomo sapiens (human)
cytoplasmInsulin-degrading enzymeHomo sapiens (human)
mitochondrionInsulin-degrading enzymeHomo sapiens (human)
peroxisomeInsulin-degrading enzymeHomo sapiens (human)
peroxisomal matrixInsulin-degrading enzymeHomo sapiens (human)
cytosolInsulin-degrading enzymeHomo sapiens (human)
external side of plasma membraneInsulin-degrading enzymeHomo sapiens (human)
cell surfaceInsulin-degrading enzymeHomo sapiens (human)
basolateral plasma membraneInsulin-degrading enzymeHomo sapiens (human)
extracellular exosomeInsulin-degrading enzymeHomo sapiens (human)
peroxisomal matrixInsulin-degrading enzymeHomo sapiens (human)
mitochondrionInsulin-degrading enzymeHomo sapiens (human)
cytosolInsulin-degrading enzymeHomo sapiens (human)
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
cytosolMethionine aminopeptidase 2Homo sapiens (human)
plasma membraneMethionine aminopeptidase 2Homo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytosolUDP-glucose 4-epimeraseHomo sapiens (human)
cytosolUDP-glucose 4-epimeraseHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nuclear speckHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nuclear bodyHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
nucleusHistone deacetylase 9Homo sapiens (human)
nucleoplasmHistone deacetylase 9Homo sapiens (human)
cytoplasmHistone deacetylase 9Homo sapiens (human)
histone deacetylase complexHistone deacetylase 9Homo sapiens (human)
transcription regulator complexHistone deacetylase 9Homo sapiens (human)
histone methyltransferase complexHistone deacetylase 9Homo sapiens (human)
nucleusHistone deacetylase 5Homo sapiens (human)
nucleoplasmHistone deacetylase 5Homo sapiens (human)
cytoplasmHistone deacetylase 5Homo sapiens (human)
Golgi apparatusHistone deacetylase 5Homo sapiens (human)
cytosolHistone deacetylase 5Homo sapiens (human)
nuclear speckHistone deacetylase 5Homo sapiens (human)
histone deacetylase complexHistone deacetylase 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (571)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1070078GPx-like activity of the compound using variable GSH/H2O2 as substrate by Lineweaver-burk plot analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID184561Inhibition of [Fe(2+)]/ascorbate-induced lipid peroxidation at 10e-5 M in rat brain homogenate1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1378380GPx-like activity of the compound assessed as H2O2 reduction by measuring oxidation of PhSH to (PhS)2 at 50 uM measured for 180 secs by spectrophotometric analysis relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 138New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.
AID1324751Antibacterial activity against Enterococcus faecium BM4105-RF measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1418686Neuroprotective activity against 6-OHDA-induced toxicity in rat PC12 cells assessed as increase in cell viability at 5 to 10 uM pretreated for 24 hrs followed by 6-OHDA challenge and measured after 12 hrs coincubated with tubastatin A by MTT assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1374899Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1600088Inhibition of human recombinant IDE harboring C110L/C171S/C178A/C257V/C414L/C573N/C590S/C789S/C812A/C819A/C904S/C966N/C974A mutant expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate preincub2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1324727Antibacterial activity against methicillin-resistant Staphylococcus aureus C1 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID186605Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 30 mg/kg at time interval- 3h1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1203634Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1374916Induction of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) protein unfolding at 100 uM by circular dichroism analysis2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1600081Inhibition of human recombinant IDE harboring C110L/C171S/C178A/C257V/C414L/C573N/C590S/C789S/C812A/C819A/C904S/C966N/C974A mutant expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 100 u2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1659540Antioxidant activity assessed as inhibition of Fe(II)-induced lipid peroxidation after 30 mins by TBARS assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Synthesis and biological evaluation of new antioxidant and antiproliferative chalcogenobiotin derivatives for bladder carcinoma treatment.
AID1406794Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID1325491Plasma concentration in Sprague-Dawley rat at 1 mg/kg bolus dose with continuous infusion of 1 mg/kg per hour measured for 24 hrs2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1659541Antioxidant activity assessed as half life of DPPH radical scavenging activity at 500 uM for 180 mins measured every 30 mins relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Synthesis and biological evaluation of new antioxidant and antiproliferative chalcogenobiotin derivatives for bladder carcinoma treatment.
AID1166889Binding affinity to human BBOX assessed as covalent modification by measuring PhSe group mass shift at 1 equivalent dose after 24 hrs by LC-MS method2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1322290Inhibition of pig APN at <2 mM using AMC-labeled substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
AID1374896Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1165409Activity of partially purified rat Thioredoxin reductase assessed as 5 umol/L AuCl3-mediated inhibition of NADPH oxidation by spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and biological evaluation of new nitrogen-containing diselenides.
AID640276Inhibition of YES1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1679971Potentiation of meropenem-induced antibacterial activity against Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 assessed as bacterial growth inhibition by measuring meropenem MIC incubated for overnight by CLSI protocol based assa2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1324756Antibacterial activity against Enterobacter cloacae ATCC 13047 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679917Synergistic antibacterial activity against carbapenem-resistant Escherichia coli isolate 34 harboring CTX-M-15, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1324730Antibacterial activity against methicillin-resistant Staphylococcus aureus C14 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679968Synergistic antibacterial activity against Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 assessed as ratio of negative logarithm of fractional inhibitory concentration index to non-hydrogen atom in presence of meropenem incubated2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID186458Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 30 mg/kg at time interval- 0.5 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID640255Inhibition of EPHA1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID186465Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 3 mg/kg at time interval- 2 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1820422Reversible covalent inhibition of SARS-CoV-2 main protease expressed in Escherichia coli BL21 competent cells using DABCYL-Val-Asn-Ser-Thr-Leu-Gln-Ser-Gly-Leu-Arg-Lys-EDANS as fluorogenic substrate assessed as reduction in product formation at 10 uM prein2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1070082Inhibition of human erythrocyte acetylcholinesterase using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by Ellman's method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1324737Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS4 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1070071GPx-like activity of the compound using 1 mM GSH/H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1324740Antibacterial activity against methicillin-resistant Staphylococcus aureus S14 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1822748Antifungal activity against Candida albicans SC5314 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1679935Growth inhibition of carbapenem-resistant Citrobacter freundii isolate 17 harboring SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1418681Neuroprotective activity against 6-OHDA-induced toxicity in rat PC12 cells assessed as increase in cell viability at 10 uM pretreated for 24 hrs followed by 6-OHDA challenge and measured after 12 hrs by MTT assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID640373Antiinvasive activity in human MDA231 cells at 10 uM after 48 hrs by Matrigel matrix assay2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1692494Inhibition of SARS-CoV2 3C-like protease expressed in Escherichia coli BL21 (DE3) cells using Mca-AVLQSGFR-K(Dnp)K as substrate by fluorescence method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
COVID-19: Drug Targets and Potential Treatments.
AID186611Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 3 mg/kg at time interval- 4 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1055213Inhibition of human recombinant AChE-induced amyloid beta (1 to 40) aggregation at 100 uM after 48 hrs by thioflavin T fluorescence assay relative to control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID1325483Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of NaOCl-induced lipid oxidation at 30 uM by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1374903Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 2.5 to 100 uM measured up to 1 min by FluoZin-2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID755348Inhibition of human recombinant soluble epoxide hydrolase using (cyano(6-methoxy-naphthelen-2-yl)methyl trans-[(3-phenyl-oxiran-2-yl)methyl] carbonate) as substrate preincubated for 5 mins prior to substrate addition by fluorescence assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.
AID1325479Antioxidant activity assessed as inhibition of AAPH-derived peroxyl radicals-induced PGR consumption2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID640253Inhibition of DDR1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID74938In vivo neuroprotective activity in gerbils (neuronal cell survival) before ischemic injury2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Design and biological evaluation of novel antioxidants containing N-t-Butyl-N-hydroxylaminophenyl moieties.
AID1582686Binding affinity to recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as protein aggregation by measuring increase in concentration-normalized scattering intensity by SAXS stud2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1820430Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as substrate by FRET assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1615708Inhibition of hexa-His-tagged human soluble epoxide hydrolase N-terminal phosphatase domain expressed in Escherichia coli BL21(DE3) pre-incubated for 30 mins before FDP substrate addition by fluorescence based assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
AID640257Inhibition of FLT3 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1884557Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) using Mca-AVLQSGFRK(Dnp)K as substrate by fluorescence assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
AID1418688Antioxidant activity against H2O2-induced oxidative stress in rat PC12 cells assessed as decrease in ROS accumulation at 5 uM preincubated for 24 hrs followed by H2O2 challenge and measured after 12 hrs coincubated with tubastatin A by DCFH-DA dye-based f2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1527046Inhibition of human recombinant HDAC5 using acetyl-Lys(trifluoroacetyl)-AMC substrate by fluorescence based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1600086Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using insulin as substrate preincubated for 10 mins followed by substrate addition and measured after 15 mins by fluorescence based assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1753931Cytoprotective activity against H2O2- induced cell death in rat PC-12 cells assessed as increase in viable cells pretreated for 12 hrs followed by H2O2 challenge by MTT assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID1418668Inhibition of recombinant human HDAC3 at 1 uM using fluorogenic HDAC substrate after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1615729Induction of stabilization of hexa-His-tagged human soluble epoxide hydrolase N-terminal phosphatase domain expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 50 uM by differential scanning fluorimetry2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
AID1820419Antiviral activity against SARS-CoV-2 USA_WA1/2020 infected in human Calu-3 cells assessed as reduction in viral RNA replication pretreated for 1 hr with compound followed by viral infection for 1.5 hrs then followed by washout the cells and re-incubated 2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1325485Inhibition of 15-LOX-mediated lipid oxidation in 10% C57BL/6J mouse plasma at 30 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID640282Inhibition of FAK phosphorylation in EGF-stimulated human MDA231 cells using [gamma32P]ATP as substrate at 50 uM after 2 hrs by scintillation counting2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1418679Neuroprotective activity against H2O2-induced toxicity in rat PC12 cells assessed as cell viability at 10 uM pretreated for 24 hrs followed by H2O2 challenge and measured after 12 hrs by MTT assay relative to control2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID640275Inhibition of VEGFR2 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1324741Antibacterial activity against methicillin-resistant Staphylococcus aureus S17 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID640247Inhibition of PKCalpha at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1406790Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID1324726Antibacterial activity against methicillin-resistant Staphylococcus aureus BRS3 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679928Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 18 harboring IMP-4 and TEM-1 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679953Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 09 harboring CTX-M-3, CTX-M-14, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID640271Inhibition of SRC at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID186606Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 30 mg/kg at time interval- 4 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1632335Binding affinity to Escherichia coli TrxR assessed as dissociation constant for reactivity at dithiol Cys135-Cys138 by liquid scintillation counting2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID186603Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 30 mg/kg at time interval- 1 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1897974Cytotoxicity against african green monkey Vero E6 cells2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
AID1434674Antitrypanosomal activity against Trypanosoma brucei bloodstream forms after 72 hrs by CellTiter-Blue fluorescence assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1679961Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Klebsiella oxytoca isolate 03 harboring SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1374907Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at >25 uM after 1 hr by circular dichroism analys2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1406795Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID363806Antioxidant activity assessed as hydroxyl radical scavenging activity2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID1166884Inhibition of human BBOX pre-incubated for 25 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID640265Inhibition of PAK1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1715840Induction of apoptosis in human HCT-116 cells assessed as increase in late apoptosis level at 40 uM incubated for 24 hrs by annexin-V/propidium iodide staining based flow cytometry relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Aglycone Ebselen and β-d-Xyloside Primed Glycosaminoglycans Co-contribute to Ebselen β-d-Xyloside-Induced Cytotoxicity.
AID1324752Antibacterial activity against Vancomycin-resistant Enterococcus measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1753923Inhibition of BACE-1 (unknown origin) at 2 uM using Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-Dnp-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by FRET assay relative to control2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID453283Antioxidant activity assessed as peroxynitrite scavenging activity in absence of NaHCO3 by fluorescent rhodamine formation assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis and antioxidant properties of new chromone derivatives.
AID1527049Inhibition of human recombinant HDAC9 using acetyl-Lys(trifluoroacetyl)-AMC substrate by fluorescence based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID640269Inhibition of RPS6KA4 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1679902Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 27 harboring CTX-M-3, CTX-M-14, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1204378Antioxidant activity assessed as glutathione peroxidase like activity after 3 mins by spectrophotometry2015European journal of medicinal chemistry, Jun-05, Volume: 97Organoselenocyanates and symmetrical diselenides redox modulators: Design, synthesis and biological evaluation.
AID1203643Cell cycle arrest in human Bel7402 cells assessed as cells accumulation at S phase at 50 uM after 48 hrs by flow cytometry (Rvb = 13.99%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1324738Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS51 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1203664Induction of apoptosis in human Bel7402 cells assessed as live cells at 50 uM after 48 hrs by flow cytometry (Rvb = 98.65%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID74937In vivo neuroprotective activity in gerbils (neuronal cell survival) after ischemic injury2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Design and biological evaluation of novel antioxidants containing N-t-Butyl-N-hydroxylaminophenyl moieties.
AID186590Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 100 mg/kg at time interval- 2 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1753930Inhibition of amyloid beta(1 to 40) secretion in human HEK293T cells transfected with human APP harboring Swedish double mutant K595N/M596L at 1 uM measured after 24 hrs by ELISA2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID1266394Inhibition of human recombinant IDO1 using L-tryptophan as substrate preincubated for 5 mins followed by substrate addition measured after 10 mins by HPLC analysis2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
AID1324749Antibacterial activity against Enterococcus faecalis ATCC 29212 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1881725Inhibition of SARS CoV PL protease incubated for 60 mins2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1679908Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 08 harboring CTX-M-14, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1506755Thiol peroxidase-like activity assessed as induction of hydrogen peroxide decomposition at 50 to 250 uM using benzenethiol incubated for 20 mins2017MedChemComm, Feb-01, Volume: 8, Issue:2
Synthesis, antioxidant and antitumoral activities of 5'-arylchalcogeno-3-aminothymidine (ACAT) derivatives.
AID1418666Inhibition of recombinant human HDAC6 using fluorogenic HDAC substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID363805Inhibition of bovine 5LOX at 10 uM2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID1324764Bacteriostatic activity against methicillin-resistant Staphylococcus aureus S22 at MIC measured up to 3 to 6 hrs by time kill analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1166883Inhibition of human BBOX pre-incubated for 20 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1166892Binding affinity to human BBOX in presence of Fe(II) by tryptophan fluorescence quenching binding assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1418683Cytoprotective activity against H2O2-induced damage in rat PC12 cells assessed as decrease in ROS accumulation preincubated for 24 hrs followed by H2O2 challenge measured after 12 hrs by DCFH-DA dye-based fluorescence analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1679958Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 17 harboring SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 64 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1330504Antioxidant activity assessed as H2O2 scavenging by measuring remaining dithiothreitol level at 0.1 equivalent after 5 mins by 1H NMR spectroscopy relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
New glutathione peroxidase mimetics-Insights into antioxidant and cytotoxic activity.
AID1822735Selectivity ratio of IC50 for inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase to IC50 for inhibition of Candida albicans Fructose-1,6-Bisphosphate Aldolase C111S mutant2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1679931Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 08 harboring CTX-M-14, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1070067GPx-like activity of the compound using 4 mM GSH/H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1632343Inhibition of recombinant Helicobacter pylori urease expressed in Escherichia coli rosetta DE3 using urea as substrate assessed as transformed cell urea splitting activity preincubated for 2 hrs followed by substrate addition measured after 2 hrs by Berth2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1527055Inhibition of Candida albicans H+-ATPase2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1324779Cytotoxicity against mouse RBCs assessed as hemolysis at 15.6 ug/ml measured after 1 hr2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1203633Antiproliferative activity against human Bel7402 cells assessed as cell viability after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1582684Binding affinity to recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as protein aggregation by measuring increase in maximum dimensions of the particles by SAXS study analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1659538Antioxidant activity assessed as half life of GPx-like activity to decompose hydrogen peroxide at 450 uM measured for 20 mins by spectrophotometer method2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Synthesis and biological evaluation of new antioxidant and antiproliferative chalcogenobiotin derivatives for bladder carcinoma treatment.
AID1324759Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1055212Glutathione peroxidase-like activity of the compound in potassium phosphate buffer assessed as GSH-mediated reduction of H2O2 measured for 10 secs by spectrophotometric analysis (Rvb = 49.5 +/- 2.6 uM/min)2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID1679900Synergistic antibacterial activity against carbapenem-resistant Morganella morganii isolate 23 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679921Growth inhibition of carbapenem-resistant Morganella morganii isolate 26 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1527047Inhibition of human recombinant HDAC6 using RHKKAc-AMC substrate by fluorescence based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID186610Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 3 mg/kg at time interval- 3h1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID186463Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 3 mg/kg at time interval- 0.5 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1324739Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS77 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679969Synergistic antibacterial activity against Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 assessed as fractional inhibitory concentration index in presence of meropenem incubated for overnight by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1070075GPx-like activity of the compound using GSH/1 mM H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1679930Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 09 harboring CTX-M-3, CTX-M-14, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID274135Inhibition of gamma radiation-induced lipid peroxidation in liposomes2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1070077GPx-like activity of the compound using GSH/0.8 mM H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1679934Growth inhibition of carbapenem-resistant Citrobacter freundii isolate 35 harboring CTX-M-3, KPC-2 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679956Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 43 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID186443Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 100 mg/kg at time interval- 0.5 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1881720Inhibition of SARS CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 substrate by FRET assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1582681Non-reversible binding affinity to immobilized recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as slow dissociation rate at 12.5 uM by SPR assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1324763Bacteriostatic activity against methicillin-resistant Staphylococcus aureus S22 at 0.5 times MIC measured up to 3 to 6 hrs by time kill analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1632344Inhibition of urease in Helicobacter pylori J99 in Brucella broth using urea as substrate after 2 hrs by Berthelot assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1203641Cell cycle arrest in human Bel7402 cells assessed as cells accumulation at Sub-G1 phase at 50 uM after 48 hrs by flow cytometry (Rvb = 1.47%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1679910Synergistic antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 43 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1820424Competitive inhibition of SARS-CoV-2 main protease assessed as inhibitor concentration dependent Km with constant Vmax at 0.5 to 10 uM using varying concentrations of DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by double reciprocal plot analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1384615Inhibition of recombinant human MIF tautomerization expressed in Escherichia coli BL21/DE3 using HPP as substrate preincubated for 15 mins followed by substrate addition measured for 3 mins2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.
AID1272928Antioxidant activity assessed as peroxide reduction rate at 80 uM using H2O2/GSH as substrate/hydrogen-donar by GPx-based assay2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Synthesis, isomerization and biological activity of novel 2-selenohydantoin derivatives.
AID1070080GPx-like activity of the compound using GSH/variable H2O2 as substrate by Lineweaver-burk plot analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1418673Antioxidant activity assessed as H2O2 radical scavenging at 10 uM up to 200 mins2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1165406Antioxidant activity assessed as glutathione peroxidase-like activity assessed as time required to reduce the thiol concentration by 50% after addition of H2O2 by UV spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and biological evaluation of new nitrogen-containing diselenides.
AID1679963Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Escherichia coli isolate 34 harboring CTX-M-15, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 64 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1324758Antibacterial activity against Klebsiella pneumoniae ATCC 27736 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID640162Antiproliferative activity against human MDA231 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID660253Toxicity in rat2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Synthesis and antitumor-evaluation of 1,3,4-thiadiazole-containing benzisoselenazolone derivatives.
AID75288In vitro glutathione peroxidase activity at 2*10e-7M using tert-butyl hydroperoxide, activity given in percentage of ebselen''s activity1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1679925Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 22 harboring CTX-M-14, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID640375Toxicity in SCID mouse xenografted with human MDA231 cells assessed as body weight loss at 60 mg/kg, ip administered 3 times a week for a total of 9 doses2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1406791Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID1600090Binding affinity to IDE in human HepG2 cells assessed as aggregation temperature at 30 uM incubated for 2 hrs by CETSA2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1679938Growth inhibition of carbapenem-resistant Klebsiella oxytoca isolate 03 harboring SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679954Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 08 harboring CTX-M-14, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 32 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID186592Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 100 mg/kg at time interval- 4 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID640252Inhibition of CDK1/cyclin B at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1582669Covalent inhibition of recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells interaction with Cy5-p22phox149-162 incubated for 10 mins in presence of TCEP by fluorescence polarization compe2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1679924Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 28 harboring TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1374895Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1679918Synergistic antibacterial activity against carbapenem-resistant Escherichia coli isolate 33 harboring CTX-M-15 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1418674Antioxidant activity assessed as tert-butyl hydroperoxide radical scavenging at 10 uM up to 200 mins2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID276475Cytotoxicity against CHO-K1 cells by Alamar blue assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID1070081GPx-like activity of the compound assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis (Rvb = 39.46 +/- 1.5 uM/min)2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1820417Antiviral activity against SARS-CoV-2 USA_WA1/2020 infected in African green monkey Vero E6 cells assessed as reduction in virus replication pretreated for 1 hr with compound followed by viral infection for 1.5 hrs then followed by washout and re-incubate2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1324757Antibacterial activity against Escherichia coli MC1061 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1662235Inhibition of bacteria NMD-12020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.
AID1679944Growth inhibition of carbapenem-resistant Klebsiella pneumoniae isolate 04 harboring CTX-M-14, VIM-1, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1418672GPx-like activity of the compound assessed as velocity for cumene hydroperoxide reduction at 80 uM in presence of GSH and NADPH by spectrophotometric analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1070084Inhibition of electric eel acetylcholinesterase using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by Ellman's method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1166886Binding affinity to human BBOX assessed as quenching of intrinsic tryptophan fluorescence at 50 to 200 uM in presence of Fe(II)2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1679922Synergistic antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 04 harboring CTX-M-14, VIM-1, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1324731Antibacterial activity against methicillin-resistant Staphylococcus aureus C16 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1418691Antioxidant activity against H2O2-induced oxidative stress in rat PC12 cells assessed as decrease in ROS accumulation preincubated for 24 hrs followed by H2O2 challenge and measured after 12 hrs coincubated with tubastatin A by DCFH-DA dye-based fluoresce2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1527056Inhibition of Aspergillus fumigatus TrxR2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1715827Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Aglycone Ebselen and β-d-Xyloside Primed Glycosaminoglycans Co-contribute to Ebselen β-d-Xyloside-Induced Cytotoxicity.
AID1324744Antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1822761Cytotoxicity against human HaCaT cells2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID660250Antiproliferative activity against human SSMC-7721 cells after 48 hrs by CCK-8 assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Synthesis and antitumor-evaluation of 1,3,4-thiadiazole-containing benzisoselenazolone derivatives.
AID1324750Antibacterial activity against Enterococcus faecalis ATCC 49533 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1881721Antiviral activity against SARS CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation incubated for 1 hr by viral plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1330671Glutathione peroxidase like activity assessed as hydrogen peroxide reduction by measuring reaction half life at 0.1 mM measured for 180 sec in presence of PhSH (Rvb = 214 mins)2016European journal of medicinal chemistry, Nov-10, Volume: 123Selenoureido-iminosugars: A new family of multitarget drugs.
AID1324722Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1897972Antiviral activity against SARS-CoV-2 infected in Vero E6 cells2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
AID1070068GPx-like activity of the compound using 3 mM GSH/H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1679911Synergistic antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 35 harboring CTX-M-3, KPC-2 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID85746The concentration producing 50% toxicity in HT-22 hippocampal cell line.2000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
New quinolinic derivatives as centrally active antioxidants.
AID1324721Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1600087Inhibition of human recombinant IDE harboring C110L/C171S/C178A/C257V/C414L/C573N/C590S/C789S/C812A/C819A/C904S/C966N/C974A mutant expressed in Escherichia coli BL21 (DE3) cells using insulin as substrate preincubated for 10 mins followed by substrate add2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID363802Inhibition of human COX22008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID186602Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 30 mg/kg at time interval- 0.5 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1556932GPx-like activity of the compound assessed as oxidation of NADPH to NADP+ by measuring optical density at 41 uM measured for 3 mins by spectrophotometry2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biochemical studies of novel organic selenides with increased selectivity for hepatocellular carcinoma and breast adenocarcinoma.
AID1406789Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID276473Inhibition of human GalE by HPAEC assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID1418689Antioxidant activity against H2O2-induced oxidative stress in rat PC12 cells assessed as decrease in ROS accumulation at 5 uM preincubated for 24 hrs followed by H2O2 challenge and measured after 12 hrs by DCFH-DA dye-based fluorescence analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1330506Antioxidant activity assessed as H2O2 scavenging by measuring remaining dithiothreitol level at 0.1 equivalent after 30 mins by 1H NMR spectroscopy relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
New glutathione peroxidase mimetics-Insights into antioxidant and cytotoxic activity.
AID1822749Antifungal activity against fluconazole resistant Candida albicans 103 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1582687Binding affinity to recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as protein aggregation by SAXS study analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID186464Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 3 mg/kg at time interval- 1 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID184572Inhibition of spontaneous lipid peroxidation at 10e-5 M in rat brain homogenate1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID640266Inhibition of PDGFRbeta at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID289341Peroxynitrite scavenging activity assessed as inhibition of DHR oxidation in presence of NaHCo32007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
2-Styrylchromones: novel strong scavengers of reactive oxygen and nitrogen species.
AID1070069GPx-like activity of the compound using 2 mM GSH/H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1324781Cytotoxicity against HEK293 cells assessed as cell death up to 10 ug/ml measured after 24 hrs by resazurin dye-based fluorescence analysis relative to untreated control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1378382GPx-like activity of the compound assessed as half life for H2O2 reduction by measuring oxidation of PhSH to (PhS)2 at 50 uM measured for 180 secs by spectrophotometric analysis relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 138New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.
AID1846328Antiviral activity against HIV 1 infected in HeLa cells transfected with CD4,TTR and LacZ gene assessed as reduction in viral replication measured after 72 hrs by ELISA2021European journal of medicinal chemistry, May-05, Volume: 217An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors.
AID1406792Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID1600084Reversible inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 1.25 uM preincubated for 30 mins followed by 100 fold compound dilution by spectrophotome2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1165412Activity of partially purified rat Thioredoxin reductase assessed as NADPH oxidation after 10 mins by spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and biological evaluation of new nitrogen-containing diselenides.
AID1679970Growth inhibition of Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 incubated for overnight by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1324774Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as reduction of biofilm at 31.3 ug/ml measured after 24 hrs by crystal violet staining based method relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID640264Inhibition of p38-gamma at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID640164Inhibition of AKT-1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1324768Antibiofilm activity against methicillin-sensitive Staphylococcus aureus ATCC 6538 assessed as reduction in biofilm mass at 2 ug/ml measured after 24 hrs by crystal violet staining based method relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679906Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 10 harboring CTX-M-14, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679962Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Escherichia coli isolate 45 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1881722Inhibition of SARS CoV-2 PL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 substrate by FRET assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1203662Induction of apoptosis in human Bel7402 cells assessed as necrotic cells at 50 uM after 48 hrs by flow cytometry (Rvb = 0.19%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1753937Protection against H2O2-induced ROS accumulation in rat PC-12 cells assessed as intracellular ROS level by measuring mean fluorescence intensity pretreated for 12 hrs followed by H2O2 challenge by DCFH-DA staining based flow cytometry2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID640256Inhibition of FGFR1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID186445Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 100 mg/kg at time interval- 2 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID640377Antitumor activity against human MDA231 cells xenografted in SCID mouse assessed as inhibition of lung metastases of cancer cells at 60 mg/kg, ip administered 3 times a week for a total of 9 doses measured on day 40 by stereomicroscopic analysis2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1822733Selectivity ratio of IC50 for inhibition of Candida albicans Fructose-1,6-Bisphosphate Aldolase C292S mutant to IC50 for inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1845235Antiviral activity against SARS-CoV-2 infected in 1 hr pretreated african green monkey Vero cells assessed as reduction of viral RNA at 10 uM allowed for 2 hrs of viral infection followed by removal of virus-drug mixture with replenishment of drug-contain2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID1600091Binding affinity to IDE in human HepG2 cells assessed as change in aggregation temperature at 30 uM incubated for 2 hrs by CETSA2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1418669Antioxidant activity assessed as inhibition of AAPH-induced peroxyl radical generation measured as trolox equivalent at 10 to 100 uM preincubated for 10 mins followed by AAPH addition and measured every minute for 120 mins by ORAC-FL assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1679904Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 19 harboring CTX-M-14 and KPC-2 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679955Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 07 harboring CTX-M-14, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 64 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1632341Inhibition of recombinant Helicobacter pylori urease expressed in Escherichia coli rosetta DE3 after 120 mins by Berthelot colorimetric analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1600092Ratio of aggregation temperature to change in aggregation temperature for binding affinity to IDE in human HepG2 cells at 30 uM incubated for 2 hrs by CETSA2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1715839Induction of apoptosis in human HCT-116 cells assessed as increase in early apoptosis level at 40 uM incubated for 24 hrs by annexin-V/propidium iodide staining based flow cytometry relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Aglycone Ebselen and β-d-Xyloside Primed Glycosaminoglycans Co-contribute to Ebselen β-d-Xyloside-Induced Cytotoxicity.
AID186604Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 30 mg/kg at time interval- 2 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1055209Activity at rat liver TrxR at 15 uM measured for 10 mins in presence of NADPH relative to control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID1679915Synergistic antibacterial activity against carbapenem-resistant Klebsiella oxytoca isolate 03 harboring SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID140764Percent survival of NMRI mice after 5 hours of intraperitoneal administration of 150 mg/kg of compound.2000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
New quinolinic derivatives as centrally active antioxidants.
AID274138Effect on gamma irradiation-induced TBARS formation in liposomes at 50 uM2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1406797Selectivity index, ratio of GI50 for human BEAS2B cells to GI50 for human HTB-54 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID1324748Antibacterial activity against Staphylococcus epidermidis ATCC 35984 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679943Growth inhibition of carbapenem-resistant Klebsiella pneumoniae isolate 14 harboring CTX-M-14, KPC-2 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID227512Glutathione peroxidase-like activity at 10x(E -4) M concentration measured as NADP+/L/min2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Screening of new antioxidant molecules using flow cytometry.
AID1324732Antibacterial activity against methicillin-resistant Staphylococcus aureus C19 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1070070GPx-like activity of the compound using 1.5 mM GSH/H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1203635Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1418696Cytotoxicity against rat PC12 cells at 20 uM in presence of tubastantin A after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1679939Growth inhibition of carbapenem-resistant Escherichia coli isolate 45 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1374898Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1679916Synergistic antibacterial activity against carbapenem-resistant Escherichia coli isolate 45 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1683016Glutathione peroxidase-like catalytic anti-lipid peroxidation activity assessed as inhibition of AAPH-induced lipid peroxidation incubated for 3 hrs using soybean lecithin/cholesterol-liposomes by TBARS assay
AID1203661Induction of apoptosis in human Bel7402 cells assessed as detection error cells at 50 uM after 48 hrs by flow cytometry (Rvb = 0.43%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1679948Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 27 harboring CTX-M-3, CTX-M-14, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 32 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID640274Inhibition of TRKB at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1822743Inhibition of Candida albicans Fructose-1,6-Bisphosphate Aldolase C157S mutant transfected in Escherichia coli BL21 (DE3) incubated for 3 mins in presence of NADH by spectrophotometric analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID186608Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 3 mg/kg at time interval- 1 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1679926Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 27 harboring CTX-M-3, CTX-M-14, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679933Growth inhibition of carbapenem-resistant Citrobacter freundii isolate 43 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1288663Antimycobacterial activity against Mycobacterium tuberculosis H37Rv mc26206 incubated for 96 hrs by resazurin microtiter assay
AID186444Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 100 mg/kg at time interval- 1 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1203644Cell cycle arrest in human Bel7402 cells assessed as cells accumulation at G2/M phase at 50 uM after 48 hrs by flow cytometry (Rvb = 16.61%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID232026Safety ratio of MTC to that of PC502000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
New quinolinic derivatives as centrally active antioxidants.
AID1557399Inhibition of recombinant human IDO1 assessed as reduction in formation of N-formylkynurenine using L-tryptophan as substrate by UV-VIS spectrometric method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1324724Antibacterial activity against methicillin-resistant Staphylococcus aureus 1 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679957Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 35 harboring CTX-M-3, KPC-2 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1374900Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1881726Inhibition of SARS CoV-2 PL protease incubated for 60 mins2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1679914Synergistic antibacterial activity against carbapenem-resistant Klebsiella oxytoca isolate 16 harboring SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID186467Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 3 mg/kg at time interval- 4 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1055219Inhibition of electric eel AChE using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 1 min by Ellman's method2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID476327Antioxidant activity assessed as ABTS+ radical scavenging activity by spectrophotometry relative to 1 mM Trolox2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Synthesis and biological evaluation of amidine, guanidine, and thiourea derivatives of 2-amino(6-trifluoromethoxy)benzothiazole as neuroprotective agents potentially useful in brain diseases.
AID1418680Neuroprotective activity against 6-OHDA-induced toxicity in rat PC12 cells assessed as increase in cell viability at 5 uM pretreated for 24 hrs followed by 6-OHDA challenge and measured after 12 hrs by MTT assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1632345Inhibition of urease in Helicobacter pylori J99 in Brucella broth using urea as substrate preincubated for 2 hrs followed by substrate addition measured after 2 hrs by Berthelot assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID660252Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Synthesis and antitumor-evaluation of 1,3,4-thiadiazole-containing benzisoselenazolone derivatives.
AID1420580Cytoprotective activity against H2O2-induced oxidative damage in human AC16 cells at 1 uM preincubated for 30 mins followed by H2O2 addition and measured after 6 hrs2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Hybrids of arenobufagin and benzoisoselenazol reducing the cardiotoxicity of arenobufagin.
AID1600083Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 0.0125 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spec2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1330505Antioxidant activity assessed as H2O2 scavenging by measuring remaining dithiothreitol level after 15 mins at 0.1 equivalent by 1H NMR spectroscopy relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
New glutathione peroxidase mimetics-Insights into antioxidant and cytotoxic activity.
AID1582688Binding affinity to recombinant human His-tagged 15N-labeled p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as compound interaction with protein at Cys196 in SH3A domain by NMR spectroscopy2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1434673Inhibition of recombinant Trypanosoma brucei His6-tagged HK1 expressed in Escherichia coli M15(pREP) harboring pQE30 using glucose as substrate after 2 hrs by spectrophotometric based glucose 6-phosphate dehydrogenase enzyme coupled assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1406793Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID1166880Inhibition of human BBOX pre-incubated for 1 min using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID75287In vitro glutathione peroxidase activity at 2*10e-7M using hydrogen peroxide, activity given in percentage of ebselen''s activity1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1820416Inhibition of GST-tagged SARS-CoV-2 main protease expressed in Escherichia coli BL21 competent cells using DABCYL-Val-Asn-Ser-Thr-Leu-Gln-Ser-Gly-Leu-Arg-Lys-EDANS as substrate measured every 10 mins for 1 hr by FRET assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1324755Antibacterial activity against Acinetobacter baumannii ATCC 19606 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1330657Glutathione peroxidase like activity assessed as hydrogen peroxide reduction by measuring reaction rate at 0.1 mM measured for 180 sec in presence of PhSH relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Selenoureido-iminosugars: A new family of multitarget drugs.
AID640254Inhibition of EGFR at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1820420Reversible covalent inhibition of SARS-CoV-2 main protease expressed in Escherichia coli BL21 competent cells using DABCYL-Val-Asn-Ser-Thr-Leu-Gln-Ser-Gly-Leu-Arg-Lys-EDANS as fluorogenic substrate assessed as reduction in product formation at 1 uM incuba2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1166885Induction of Zn(II) from human BBOX assessed as zinc release by fluorescence based assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1615730Inhibition of hexa-His-tagged human soluble epoxide hydrolase C-terminal hydrolase domain expressed in Escherichia coli BL21(DE3) pre-incubated for 30 mins before DiFMUP substrate addition by fluorescence based assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
AID640258Inhibition of FYN at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1324728Antibacterial activity against methicillin-resistant Staphylococcus aureus C2 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1715830Induction of cell cycle arrest at S phase in human HCT-116 cells at 40 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Aglycone Ebselen and β-d-Xyloside Primed Glycosaminoglycans Co-contribute to Ebselen β-d-Xyloside-Induced Cytotoxicity.
AID1374904Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 2.5 to 100 uM measured up to 1 min by FluoZin-2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1418670GPx-like activity of the compound assessed as velocity for H2O2 reduction at 80 uM in presence of GSH and NADPH by spectrophotometric analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1846327Inhibition of HIV 1 capsid CTD dimerization incubated for 5 hrs by TR-FRET assay2021European journal of medicinal chemistry, May-05, Volume: 217An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors.
AID1679903Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 22 harboring CTX-M-14, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1615721Inhibition of hydrolase activity of full length human soluble epoxide hydrolase pre-incubated for 30 mins before PHOME substrate addition by fluorescence based assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
AID13254871-octanol-water partition coefficient, log P of the compound2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1679912Synergistic antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 17 harboring SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1431158Binding affinity to soybean p1 15-LOX at 100 pmol after 1 hr by magnetic microbead affinity selection screening method2016Journal of natural products, 11-23, Volume: 79, Issue:11
Magnetic Microbead Affinity Selection Screening (MagMASS) of Botanical Extracts for Inhibitors of 15-Lipoxygenase.
AID640248Inhibition of IGF1R at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1632338Reversible inhibition of Sporosarcina pasteurii CCM 2056 urease using urea as substrate assessed as ammonia levels after 120 mins by fast dilution assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1632339Steady state inhibition of Sporosarcina pasteurii CCM 2056 urease using urea as substrate assessed as inhibition constant for final enzyme conformation-inhibitor complex by measuring ammonia levels after 120 mins by phenol-hypochlorite method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID85744The minimum tolerated concentration by MTT reduction assay in HT-22 hippocampal cell line.2000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
New quinolinic derivatives as centrally active antioxidants.
AID274139Glutathione peroxidase activity assessed by GSH-GSSG coupled assay2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1582671Covalent inhibition of recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells interaction with Cy5-p22phox149-162 incubated for 2 hrs by fluorescence polarization competition assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1324729Antibacterial activity against methicillin-resistant Staphylococcus aureus C7 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1683020Cytotoxicity against human HeLa cells assessed as cell viability at 20 uM measured after 15 hrs by MTT assay relative to control
AID1679936Growth inhibition of carbapenem-resistant Klebsiella oxytoca isolate 16 harboring SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1582685Binding affinity to recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as protein aggregation by measuring increase in SAXS-derived radius of gyration by SAXS study analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1679907Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 09 harboring CTX-M-3, CTX-M-14, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1718098Inhibition of SARS-CoV papain-like protease using ubiquitin-AMC as substrate preincubated for 60 mins followed by substrate addition2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1637705Antioxidant activity assessed as glutathione peroxidase-like activity in phosphate buffer measured as initial rate for the reduction of tert-butyl hydroperoxide by GSH at 80 uM in presence of NADPH by coupled reductase assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.
AID186609Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 3 mg/kg at time interval- 2 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1203636Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1325477Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of AAPH-derived peroxyl radicals-induced pyranine consumption at 50 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1582670Ratio of Ki for recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells in presence of TCEP to Ki for recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Esc2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID640251Inhibition of Aurora B at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1600093Binding affinity to IDE in human HepG2 cells assessed as cell penetration at 30 uM incubated for 2 hrs by CETSA relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID186466Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 3 mg/kg at time interval- 3h1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID274142Antioxidant activity assessed by singlet oxygen quenching ability2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1679960Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Klebsiella oxytoca isolate 16 harboring SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID640376Apparent toxicity in SCID mouse xenografted with human MDA231 cells at 60 mg/kg, ip administered 3 times a week for a total of 9 doses2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1070066Antioxidant activity assessed as H2O2 scavenging activity at 50 to 200 uM after 10 hrs by ferrous ion oxidation-xylenol orange assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1166890Binding affinity to human BBOX assessed as covalent modification by measuring PhSe group mass shift at 10 equivalent dose after 24 hrs by non-denaturating LC-MS method2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1070083Inhibition of equine serum butyrylcholinesterase using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by Ellman's method2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1378379GPx-like activity of the compound assessed as velocity for H2O2 reduction by measuring oxidation of PhSH to (PhS)2 at 50 uM measured for 180 secs by spectrophotometric analysis2017European journal of medicinal chemistry, Sep-29, Volume: 138New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.
AID1753924Inhibition of BACE-1 (unknown origin) using Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-Dnp-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by FRET assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID640270Inhibition of SGK3 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1055217Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID1324725Antibacterial activity against methicillin-resistant Staphylococcus aureus 2 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1615722Inhibition of phosphatase activity of full length human soluble epoxide hydrolase pre-incubated for 30 mins before FDP substrate addition by fluorescence based assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
AID1679964Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Escherichia coli isolate 33 harboring CTX-M-15 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 64 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679959Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 05 harboring SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1632337Competitive inhibition of Sporosarcina pasteurii CCM 2056 urease using urea as substrate assessed as ammonia levels after 120 mins by Lineweaver-Burk plot analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1679929Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 10 harboring CTX-M-14, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID453284Antioxidant activity assessed as peroxynitrite scavenging activity in presence of NaHCO3 by fluorescent rhodamine formation assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis and antioxidant properties of new chromone derivatives.
AID1324734Antibacterial activity against methicillin-resistant Staphylococcus aureus G6 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679932Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 07 harboring CTX-M-14, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1324720Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 6538 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679901Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 28 harboring TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID515382Antioxidant activity assessed as peroxynitrite scavenging activity by spectrophotometry in absence of NaHCO32010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
2,3-diarylxanthones as strong scavengers of reactive oxygen and nitrogen species: a structure-activity relationship study.
AID186591Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 100 mg/kg at time interval- 3h1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID640267Inhibition of PIM1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1822757Toxicity in po dosed rat assessed as lethal dose2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1679927Growth inhibition of carbapenem-resistant Enterobacter cloacae isolate 19 harboring CTX-M-14 and KPC-2 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679913Synergistic antibacterial activity against carbapenem-resistant Citrobacter freundii isolate 05 harboring SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID225222Antioxidative property against stable murine-murine hybridoma (Mark 3) cell line2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Screening of new antioxidant molecules using flow cytometry.
AID1679920Synergistic antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 14 harboring CTX-M-14, KPC-2 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1888015Inhibition of recombinant human IDO1 expressed in Escherichia coli assessed as reduction in formation of N-formylkynurenine by measuring apparent inhibition constant using L-tryptophan as substrate preincubated with compound for 5 mins followed substrate 2022European journal of medicinal chemistry, Jan-05, Volume: 227Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase.
AID1324765Bactericidal activity against methicillin-resistant Staphylococcus aureus S22 at 4 times MIC measured after 24 hrs by time kill analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID85745The concentration producing 50% protection against L-HCA-mediated neurotoxicity in HT-22 hippocampal cell line.2000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
New quinolinic derivatives as centrally active antioxidants.
AID1406796Selectivity index, ratio of GI50 for human 184B5 cells to GI50 for human MCF7 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.
AID186462Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 30 mg/kg at time interval- 4 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID276474Cytotoxicity against Trypanosoma brucei by Alamar blue assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID227511Glutathione peroxidase-like activity at 10x(E -3) M concentration as NADP+/L/min2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Screening of new antioxidant molecules using flow cytometry.
AID1632340Competitive reversible inhibition of recombinant Helicobacter pylori urease infected in transformed Escherichia coli rosetta DE3 after 120 mins by Lineweaver-Burk plot analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1637704Antioxidant activity assessed as glutathione peroxidase-like activity in phosphate buffer measured as initial rate for the reduction of cumene hydroperoxide by GSH at 80 uM in presence of NADPH by coupled reductase assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.
AID1374909Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from 3 types of Cys9-type Zn fingers at >25 uM after 1 hr by circular2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1324733Antibacterial activity against methicillin-resistant Staphylococcus aureus G1 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679942Growth inhibition of carbapenem-resistant Escherichia coli isolate 06 harboring CTX-M-14, CTX-M-3 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1324753Antibacterial activity against Listeria monocytogenes ATCC 19115 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1527057Substrate activity at Cryptosporidium parvum glucose 6-phosphate isomerase2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1820421Reversible covalent inhibition of SARS-CoV-2 main protease expressed in Escherichia coli BL21 competent cells using DABCYL-Val-Asn-Ser-Thr-Leu-Gln-Ser-Gly-Leu-Arg-Lys-EDANS as fluorogenic substrate assessed as reduction in product formation at 10 uM incub2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID1679967Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 04 harboring CTX-M-14, VIM-1, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1449190Inhibition of C-terminal His-tagged Mycobacterium tuberculosis Ag85C expressed in Escherichia coli C41 (DE3) at 2.5 to 50 uM after 1 hr by resorufin butyrate-based fluorescence assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.
AID640261Inhibition of INSR at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID276470Inhibition of Trypanosoma brucei GalE at 50 uM2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID1822750Antifungal activity against fluconazole resistant Candida albicans 7781 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1070074GPx-like activity of the compound using GSH/1.2 mM H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1055216Inhibition of human erythrocyte AChE using acetylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 1 min by Ellman's method2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID1820418Distribution coefficient, logD of compound at pH 7.4 by shake flask method2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
AID74947In vitro inhibitory activity against lipid peroxidation in gerbils2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Design and biological evaluation of novel antioxidants containing N-t-Butyl-N-hydroxylaminophenyl moieties.
AID1324778Cytotoxicity against mouse RBCs assessed as hemolysis up to 7.8 ug/ml measured after 1 hr2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324747Antibacterial activity against methicillin-resistant Staphylococcus aureus USA600 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1753936Protection against 6-OHDA-induced ROS accumulation in rat PC-12 cells assessed as intracellular ROS level by measuring mean fluorescence intensity pretreated for 12 hrs followed by 6-OHDA challenge by DCFH-DA staining based flow cytometry2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID1676053Irreversible inhibition of recombinant Clostridium botulinum N-terminal 6His-tagged BoNT/A (1 to 425 residues) light chain expressed in Escherichia coli BL21 (DE3) assessed as ratio of Kinact/Ki2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.
AID1897971Inhibition of SARS-CoV-2 main protease2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
AID1822747Inhibition of Candida albicans Fructose-1,6-Bisphosphate Aldolase C111S mutant transfected in Escherichia coli BL21 (DE3) incubated for 3 mins in presence of NADH by spectrophotometric analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID363800Inhibition of bovine COX12008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID1324785Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 using 1 10'6CFU/ml measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1204377Antioxidant activity assessed as DPPH free radical scavenging activity after 30 mins by spectrophotometry2015European journal of medicinal chemistry, Jun-05, Volume: 97Organoselenocyanates and symmetrical diselenides redox modulators: Design, synthesis and biological evaluation.
AID1715826Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Aglycone Ebselen and β-d-Xyloside Primed Glycosaminoglycans Co-contribute to Ebselen β-d-Xyloside-Induced Cytotoxicity.
AID640262Inhibition of LYN at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1374910Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from from 3 types of Cys9-type Zn fingers at >25 uM after 1 hr by cir2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1632342Inhibition of recombinant Helicobacter pylori urease expressed in Escherichia coli rosetta DE3 using urea as substrate assessed as transformed cell urea splitting activity after 2 hrs by Berthelot assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1679937Growth inhibition of carbapenem-resistant Citrobacter freundii isolate 05 harboring SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1527050Inhibition of N-terminal poly-histidine tagged recombinant QSOX1 (33 to 546 residues) (unknown origin) expressed in Rosetta-gami B (DE3) cells using using reduced denatured RNAse A substrate by ROS-Glo assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1418682Neuroprotective activity against H2O2-induced toxicity in rat PC12 cells assessed as cell viability at 5 to 10 uM pretreated for 24 hrs followed by H2O2 challenge and measured after 12 hrs coincubated with tubastatin A by MTT assay relative to control2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1679949Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 22 harboring CTX-M-14, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID186607Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 3 mg/kg at time interval- 0.5 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1330503Antioxidant activity assessed as H2O2 scavenging by measuring remaining dithiothreitol level at 0.1 equivalent after 3 mins by 1H NMR spectroscopy relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
New glutathione peroxidase mimetics-Insights into antioxidant and cytotoxic activity.
AID1418684Cytoprotective activity against H2O2-induced damage in rat PC12 cells assessed as decrease in ROS accumulation preincubated for 24 hrs followed by H2O2 challenge measured after 12 hrs by DCFH-DA dye-based inverted fluorescence microscopic analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1418675Antioxidant activity assessed as cumene hydroperoxide radical scavenging at 10 uM up to 200 mins2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID186447Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 100 mg/kg at time interval- 4 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1679919Synergistic antibacterial activity against carbapenem-resistant Escherichia coli isolate 06 harboring CTX-M-14, CTX-M-3 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1324754Antibacterial activity against Mycobacterium smegmatis MC2-155 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1418677Cytotoxicity against rat PC12 cells at 20 uM after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1679951Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 18 harboring IMP-4 and TEM-1 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 32 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679941Growth inhibition of carbapenem-resistant Escherichia coli isolate 33 harboring CTX-M-15 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID640374Antitumor activity against human MDA231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 60 mg/kg, ip administered 3 times a week for a total of 9 doses measured on day 402012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1845236Inhibition of SARS-CoV-2 MPro2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID1070072GPx-like activity of the compound using GSH/1.6 mM H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1679966Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 14 harboring CTX-M-14, KPC-2 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1325478Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of SIN-1-derived peroxynitrite-induced lipid oxidation at 50 uM by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1322221Antioxidant activity assessed as inhibition of Fe2+-induced thiobarbituric acid reactive substance formation in phospholipids extracted from egg yolk by measuring malondialdehyde levels per mg of triglycerides at 100 uM after 1 hr by UV-Vis spectrophotome2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and evaluation of dihydropyrimidinone-derived selenoesters as multi-targeted directed compounds against Alzheimer's disease.
AID1679876Covalent inhibition of Escherichia coli NDM-1 using nitrocefin as substrate2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1374901Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID640372Antiangiogenic activity in human MDA231 cells assessed as inhibition of cell migration at 10 uM after 12 to 24 hrs by wound healing migration assay2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1683015Glutathione peroxidase-like catalytic antioxidant activity in pH 7 phosphate buffer assessed as catalytic reduction of H2O2 by measuring initial velocity at 0.2 mM and 25 degreeC using reduced DTT as di-thiol co-substrate in presence of NADPH by UV absorb
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1324745Antibacterial activity against methicillin-resistant Staphylococcus aureus USA200 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1374915Induction of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) protein unfolding at 100 uM by circular dichroism analysis2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1884558Antiviral activity against SARS COV-2 infected in vero cells assessed as inhibition of viral replication measured after 72 hrs by RT-qPCR method2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
AID1325476Antioxidant activity assessed as inhibition of Meo-AMVN-derived peroxyl radicals-induced fucoxanthin consumption at 50 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID276472Inhibition of Trypanosoma brucei GalE by HPAEC assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID1324760Antibacterial activity against Salmonella enterica ATCC 14028 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1679950Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 19 harboring CTX-M-14 and KPC-2 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1330507Antioxidant activity assessed as H2O2 scavenging by measuring remaining dithiothreitol level at 0.1 equivalent after 60 mins by 1H NMR spectroscopy relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
New glutathione peroxidase mimetics-Insights into antioxidant and cytotoxic activity.
AID1203663Induction of apoptosis in human Bel7402 cells assessed as apoptotic cells at 50 uM after 48 hrs by flow cytometry (Rvb = 0.73%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1514964Inhibition of Aeromonas hydrophila ATCC 7966 CphA expressed in Escherichia coli LMG194 at 50 uM using CPC-1 as substrate preincubated for 10 mins followed by substrate addition by fluorescence assay relative to control2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1582683Binding affinity to recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as increase in protein molecular weight at 200 uM by ESI/LC-MS analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID186459Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 30 mg/kg at time interval- 1 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1324736Antibacterial activity against methicillin-resistant Staphylococcus aureus G14 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1325486Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of NpEP-derived singlet oxygen-induced lipid oxidation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1070076GPx-like activity of the compound using variable GSH/H2O2 as substrate assessed as catalytic efficiency by Lineweaver-burk plot analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1384614Inhibition of recombinant human MIF tautomerization expressed in Escherichia coli BL21/DE3 using dopa as substrate2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.
AID640260Inhibition of IKKepsilon at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1685583Antiviral activity against SARS CoV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis2021RSC medicinal chemistry, Jan-01, Volume: 12, Issue:1
Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M
AID1322291Inhibition of pig LAP at <2 mM using AMC-labeled substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
AID1632336Inhibition of Sporosarcina pasteurii CCM 2056 urease using urea as substrate assessed as ammonia levels by phenol-hypochlorite method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1679947Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 28 harboring TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 32 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679965Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Escherichia coli isolate 06 harboring CTX-M-14, CTX-M-3 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb >= 128 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679909Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 07 harboring CTX-M-14, TEM-1 and SHV-12 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1582668Covalent inhibition of recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells interaction with Cy5-p22phox149-162 incubated for 10 mins by fluorescence polarization competition assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1324767Antibiofilm activity against methicillin-sensitive Staphylococcus aureus ATCC 6538 assessed as reduction of biofilm at 15.6 ug/ml measured after 24 hrs by crystal violet staining based method relative to untreated control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324723Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID186461Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 30 mg/kg at time interval- 3h1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1325480Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of AAPH-derived peroxyl radicals-induced lipid hydroperoxide formation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID640268Inhibition of PLK4 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1374902Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374897Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1324761Antibacterial activity against Staphylococcus epidermidis ATCC 12228 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1898064Inhibition of SARS-CoV2 main protease2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
AID640163Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1203638Inhibition of rat liver TrxR assessed as increase in absorbance by DTNB assay2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID1679923Growth inhibition of carbapenem-resistant Morganella morganii isolate 23 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1822739Inhibition of Candida albicans Fructose-1,6-Bisphosphate Aldolase C292S mutant transfected in Escherichia coli BL21 (DE3) incubated for 3 mins in presence of NADH by spectrophotometric analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1679945Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Morganella morganii isolate 26 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 64 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1679905Synergistic antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 18 harboring IMP-4 and TEM-1 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1070079GPx-like activity of the compound using GSH/variable H2O2 as substrate assessed as catalytic efficiency by Lineweaver-burk plot analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID227510Glutathione peroxidase-like activity at 10x(E -2) M concentration as NADP+/L/min2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Screening of new antioxidant molecules using flow cytometry.
AID515380Antioxidant activity assessed as peroxynitrite scavenging activity by spectrophotometry in presence of NaHCO32010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
2,3-diarylxanthones as strong scavengers of reactive oxygen and nitrogen species: a structure-activity relationship study.
AID1166882Inhibition of human BBOX pre-incubated for 15 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID139507Body temperature of NMRI mice after 30 minutes of intraperitoneal administration of 150 mg/kg compound.2000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
New quinolinic derivatives as centrally active antioxidants.
AID1527053Inhibition of Clostridium difficile toxin B2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1679946Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Morganella morganii isolate 23 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 64 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1203642Cell cycle arrest in human Bel7402 cells assessed as cells accumulation at G1 phase at 50 uM after 48 hrs by flow cytometry (Rvb = 62.60%)2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
AID640259Inhibition of HER2 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1884045Inhibition of SARS-CoV-2 papain-like protease preincubated for 60 mins2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1418671GPx-like activity of the compound assessed as velocity for tert-butyl hydroperoxide reduction at 80 uM in presence of GSH and NADPH by spectrophotometric analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
AID1324746Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1166881Inhibition of human BBOX pre-incubated for 10 mins using TBS-protected fluorescein probe and Fe (II) (Fe(NH4)2(SO4)2 salt by fluoride release assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1637703Antioxidant activity assessed as glutathione peroxidase-like activity in phosphate buffer measured as initial rate for the reduction of hydrogen peroxidase by GSH at 80 uM in presence of NADPH by coupled reductase assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1324743Antibacterial activity against methicillin-resistant Staphylococcus aureus S24 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1322289Inhibition of human APN at <2 mM using AMC-labeled substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
AID1679952Potentiation of meropenem-induced antibacterial activity against carbapenem-resistant Enterobacter cloacae isolate 10 harboring CTX-M-14, TEM-1 and SHV-12 assessed as meropenem MIC by CLSI protocol based assay (Rvb = 64 ug/ml)2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1058679Antioxidant activity assessed as hydrogen peroxide radical scavenging activity at 12.5 uM after 10 hrs by horseradish peroxidase assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.
AID1753925Glutathione peroxidase-like activity in pH 7.5 potassium phosphate buffer assessed as catalytic reduction of H2O2 by measuring initial velocity at 25 degreeC using GSH in presence of NADPH by UV absorbance analysis (Rvb = 30.41+/- 2.06 microM/min)2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID1600069Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometri2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1753927Neuroprotective activity against H2O2-induced cell damage in rat PC-12 cells assessed as decrease in cell death at 10 uM pretreated for 12 hrs followed by H2O2 challenge by MTT assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID232979Glutathione peroxidase-like activity in relative to Ebselen glutathione peroxidase-like activity2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Screening of new antioxidant molecules using flow cytometry.
AID1055210Antioxidant activity assessed as peroxynitrite scavenging activity by Evans blue dye-based spectrophotometric analysis relative to control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID640263Inhibition of MET at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1582682Binding affinity to immobilized recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells at 12.5 uM in presence of TCEP by SPR assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1055211Antioxidant activity assessed as hydrogen peroxide scavenging activity after 10 hrs by FOX assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID1527052Inhibition of inositol monophosphatase (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1055218Inhibition of equine serum BuChE using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 1 min by Ellman's method2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen.
AID1822751Antifungal activity against fluconazole resistant Candida albicans 904 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID186588Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 100 mg/kg at time interval- 0.5 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1715828Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Aglycone Ebselen and β-d-Xyloside Primed Glycosaminoglycans Co-contribute to Ebselen β-d-Xyloside-Induced Cytotoxicity.
AID186446Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 100 mg/kg at time interval- 3h1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1715829Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Aglycone Ebselen and β-d-Xyloside Primed Glycosaminoglycans Co-contribute to Ebselen β-d-Xyloside-Induced Cytotoxicity.
AID274137Inhibition of horseradish peroxidase by spectrophotometric method2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1166887Binding affinity to human BBOX assessed as quenching of intrinsic tryptophan fluorescence at 50 to 200 uM in absence of Fe(II)2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1324742Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1822734Selectivity ratio of IC50 for inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase to IC50 for inhibition of Candida albicans Fructose-1,6-Bisphosphate Aldolase C157S mutant2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1845234Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) using Mca-AVLQ SGFR-K(Dnp)K as substrate by EnVision multimode plate reader analysis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID640273Inhibition of TIE1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID640250Inhibition of Aurora A at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1324762Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 at 0.5 times MIC measured after 24 hrs by time kill analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1600082Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 1.25 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectr2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1324735Antibacterial activity against methicillin-resistant Staphylococcus aureus G12 measured after overnight incubation by broth double-dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID640249Inhibition of ABL1 at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1322288Non-covalent/mixed type inhibition of recombinant human MetAP2 using Met-AMC as substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
AID1058683Antioxidant activity assessed as hydrogen peroxide radical scavenging activity at 20 to 100 uM after 10 hrs by horseradish peroxidase assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.
AID1527051Effect on SOD activity in brain of rat with ischemia/reperfusion injury assessed as enzyme activity per mg protein2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1070073GPx-like activity of the compound using GSH/1.4 mM H2O2 as substrate assessed as GSH-mediated H2O2 reduction at 80 uM at pH 7.5 measured for 10 secs by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
AID1718099Inhibition of SARS-CoV2 papain-like protease using ubiquitin-AMC as substrate preincubated for 60 mins followed by substrate addition2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID640272Inhibition of SYK at 1 uM2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
AID1810186Inhibition of SARS coronavirus 2 3 main viral protease 3-chymotrypsin-like activity expressed in Escherichia coli using Dabcyl-VNSTLQSGLRK(FAM)MA as substrate measured by fluorescence intensity assay2022ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1
Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors.
AID1683014Glutathione peroxidase-like catalytic antioxidant activity in pH 7 phosphate buffer assessed as catalytic reduction of H2O2 by measuring initial velocity at 100 uM and 25 degreeC using GSH as mono-thiol co-substrate in presence of NADPH by UV absorbance a
AID660251Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Synthesis and antitumor-evaluation of 1,3,4-thiadiazole-containing benzisoselenazolone derivatives.
AID1679899Synergistic antibacterial activity against carbapenem-resistant Morganella morganii isolate 26 assessed as fractional inhibitory concentration index in presence of meropenem by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID289337Peroxynitrite scavenging activity assessed as inhibition of DHR oxidation2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
2-Styrylchromones: novel strong scavengers of reactive oxygen and nitrogen species.
AID1527054Inhibition of Bacillus anthracis TrxR2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID186589Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 100 mg/kg at time interval- 1 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1822756Inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase transfected in Escherichia coli BL21 (DE3) incubated for 3 mins in presence of NADH by spectrophotometric analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1527048Inhibition of human recombinant HDAC8 using RHKAcKAc-AMC substrate by fluorescence based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Development and Therapeutic Potential of Selenazo Compounds.
AID1679940Growth inhibition of carbapenem-resistant Escherichia coli isolate 34 harboring CTX-M-15, TEM-1 and SHV-12 by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1166891Binding affinity to human BBOX by tryptophan fluorescence quenching binding assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Ejection of structural zinc leads to inhibition of γ-butyrobetaine hydroxylase.
AID1374908Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at >25 uM after 1 hr by circular dichroism analys2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1058680Antioxidant activity assessed as hydrogen peroxide radical scavenging activity at 25 uM after 10 hrs by horseradish peroxidase assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.
AID186460Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 30 mg/kg at time interval- 2 hr1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzoselenazolinone derivatives designed to be glutathione peroxidase mimetics feature inhibition of cyclooxygenase/5-lipoxygenase pathways and anti-inflammatory activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1803933high-throughput activity assay from Article 10.1038/s41586-020-2223-y: \\Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors \\2020Nature, 06, Volume: 582, Issue:7811
Structure of M
AID1801388Inhibition Assay from Article 10.1111/cbdd.12572: \\Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.\\2015Chemical biology & drug design, Nov, Volume: 86, Issue:5
Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.
AID1799792Tautomerase Enzyme Assay from Article 10.1074/jbc.M110.113951: \\Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action.\\2010The Journal of biological chemistry, Aug-20, Volume: 285, Issue:34
Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1800476EMSA from Article 10.1021/cb500512z: \\Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication\\2014ACS chemical biology, Oct-17, Volume: 9, Issue:10
Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (819)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (4.15)18.7374
1990's138 (16.85)18.2507
2000's259 (31.62)29.6817
2010's268 (32.72)24.3611
2020's120 (14.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.68 (24.57)
Research Supply Index6.74 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index72.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (1.07%)5.53%
Reviews60 (7.15%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other770 (91.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression? [NCT05117710]Phase 150 participants (Anticipated)Interventional2021-04-22Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients [NCT04484025]Phase 260 participants (Anticipated)Interventional2021-10-12Enrolling by invitation
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease [NCT03325790]Phase 2149 participants (Actual)Interventional2017-09-28Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005 [NCT04677972]Phase 3254 participants (Actual)Interventional2022-08-02Active, not recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients [NCT04483973]Phase 260 participants (Anticipated)Interventional2021-08-27Enrolling by invitation
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus [NCT00762671]Phase 2/Phase 360 participants (Actual)Interventional1999-05-31Completed
Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease [NCT02603081]Phase 1/Phase 240 participants (Actual)Interventional2015-12-31Completed
A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL) [NCT02779192]Phase 2180 participants (Anticipated)Interventional2018-11-30Not yet recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity [NCT02819856]Phase 280 participants (Anticipated)Interventional2017-07-21Enrolling by invitation
Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss [NCT01451853]Phase 280 participants (Anticipated)Interventional2018-01-15Not yet recruiting
Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift [NCT01444846]Phase 283 participants (Actual)Interventional2011-09-30Completed
A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects [NCT01452607]Phase 132 participants (Actual)Interventional2006-05-31Completed
A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients [NCT03013400]Phase 260 participants (Actual)Interventional2017-10-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03325790 (4) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAE)
NCT03325790 (4) [back to overview]Trough Plasma Concentration of SPI-1005
NCT03325790 (4) [back to overview]Efficacy of SPI-1005 on Hearing Loss
NCT03325790 (4) [back to overview]Efficacy of SPI-1005 on Word Recognition Score

Number of Participants With Treatment Emergent Adverse Events (TEAE)

"Number and severity of adverse events in patients treated with placebo versus SPI-1005.~Outcome Measure 1 includes all adverse events, including those which are not reported in the Adverse Event module, i.e., adverse events which did not result in death, were not Serious Adverse Events, and which were below the frequency threshold (5%) in any arm as required for reporting." (NCT03325790)
Timeframe: 8 weeks

,,
InterventionParticipants (Count of Participants)
Total Number of Patients with Treatment Emergent Adverse Events (TEAE)Number of Patients with Mild TEAENumber of Patients with Moderate TEAENumber of Patients with Severe TEAE
200mg SPI-1005 Twice Daily (BID)201830
400mg SPI-1005 BID201872
Placebo191560

[back to top]

Trough Plasma Concentration of SPI-1005

Trough plasma concentration of SPI-1005 (ebselen) will be determined at certain time intervals (NCT03325790)
Timeframe: 2 weeks, 4 weeks, 8 weeks

,
Interventionng/mL (Mean)
2 weeks4 weeks8 weeks
200mg SPI-1005 Twice Daily (BID)27.219.70
400mg SPI-1005 BID48.440.60

[back to top]

Efficacy of SPI-1005 on Hearing Loss

Improvement in sensorineural hearing loss from baseline using Pure Tone Audiometry (NCT03325790)
Timeframe: 8 weeks

InterventionParticipants (Count of Participants)
Threshold Improvement from Baseline >=10 dB in at least 1 low frequency (250, 500, or 1000 Hz)72572366Threshold Improvement from Baseline >=10 dB in at least 1 low frequency (250, 500, or 1000 Hz)72572367Threshold Improvement from Baseline >=10 dB in at least 1 low frequency (250, 500, or 1000 Hz)72572368Threshold Improvement >=10 dB in 2 adjacent low frequencies (250 and 500 Hz, or 500 and 1000 Hz)72572366Threshold Improvement >=10 dB in 2 adjacent low frequencies (250 and 500 Hz, or 500 and 1000 Hz)72572367Threshold Improvement >=10 dB in 2 adjacent low frequencies (250 and 500 Hz, or 500 and 1000 Hz)72572368
NoYes
Placebo15
200mg SPI-1005 Twice Daily (BID)16
400mg SPI-1005 BID25
Placebo26
200mg SPI-1005 Twice Daily (BID)26
400mg SPI-1005 BID16
Placebo8
200mg SPI-1005 Twice Daily (BID)7
400mg SPI-1005 BID15
Placebo33
200mg SPI-1005 Twice Daily (BID)35

[back to top]

Efficacy of SPI-1005 on Word Recognition Score

Improvement in Words-in-Noise (WIN) test score from baseline. WIN test score, 0-35 words, in which a higher score means a better outcome. (NCT03325790)
Timeframe: 8 weeks

InterventionParticipants (Count of Participants)
WIN Score Improvement from Baseline >=10%72572368WIN Score Improvement from Baseline >=10%72572366WIN Score Improvement from Baseline >=10%72572367WIN Score Improvement from Baseline >=20%72572368WIN Score Improvement from Baseline >=20%72572366WIN Score Improvement from Baseline >=20%72572367WIN Score Improvement from Baseline >= 4 words72572366WIN Score Improvement from Baseline >= 4 words72572367WIN Score Improvement from Baseline >= 4 words72572368
YesNo
Placebo23
200mg SPI-1005 Twice Daily (BID)23
400mg SPI-1005 BID30
Placebo18
200mg SPI-1005 Twice Daily (BID)18
400mg SPI-1005 BID10
Placebo19
200mg SPI-1005 Twice Daily (BID)17
400mg SPI-1005 BID27
Placebo22
200mg SPI-1005 Twice Daily (BID)24
400mg SPI-1005 BID13
Placebo14
200mg SPI-1005 Twice Daily (BID)13
400mg SPI-1005 BID24
Placebo27
200mg SPI-1005 Twice Daily (BID)28
400mg SPI-1005 BID16

[back to top]